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ABSTRACT 
 
Genistein is a phytoestrogen commonly found in plants such as soybeans, lentils, and 
chickpeas. Humans and animals are most primarily exposed to genistein through the consumption 
soy and soy-based dietary products. Human exposure to genistein varies based on diet, but is 
present in many populations of adults and children. Genistein can bind to and signal through 
estrogen receptors. Therefore, it has the potential to mimic, enhance, or impair the estradiol 
biosynthesis pathway, and is categorized as an endocrine disrupting chemical. This is of concern 
to human health because genistein-induced effects on the steroidogenic pathway can result in 
adverse, long-term effects on female fertility, cardiovascular, bone, and overall health.  
The ovary is an estrogen receptor-rich tissue, and plays a key role in the regulation of 
female fertility. This is because the ovary’s main functional unit, the follicle, is responsible for the 
production of sex steroid hormones and consists of the oocyte necessary for fertilization. In the 
adult ovary, the follicle is present in all stages ranging from the immature primordial follicle to the 
most mature antral follicle. The antral follicle is one of the most important follicle types because 
it is the primary producer of sex steroid hormones in the ovary, and it is the only follicle type 
capable of growing to the point of ovulation. Therefore, any effects on folliculogenesis can 
adversely affect female fertility. 
Crosstalk between the theca and granulosa cells of the antral follicle is responsible for the 
production of sex steroid hormones that are necessary for fertility and overall female health. 
Enzymes in the theca cells metabolize cholesterol to estradiol precursor hormones such as 
progesterone and testosterone. The androgens can pass the basal membrane and enter the granulosa 
cells to be further metabolized to estrone and estradiol. Any alteration in this highly regulated 
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enzymatic process could adversely affects steroid hormone production. Normal follicle growth and 
proper steroid hormone production are necessary to maintain normal female fertility. 
Thus, I hypothesized that direct exposure to genistein inhibits antral follicle growth and 
alters the estradiol biosynthesis pathway. To test this hypothesis, I directly exposed intact antral 
follicles to 6 and 36 µM of genistein for 18-96 hours (h). After each 24 h time point, I measured 
growth, steroid hormone production, and expression of steroidogenic enzymes. Additionally after 
18 h, I measured the expression of apoptotic factors and cell cycle regulators to determine growth 
inhibition. After 24 h of culture, I found that genistein exposure significantly inhibited antral 
follicle growth, and that this inhibition continued until the end of the culture period at 96 h. Next, 
I found that genistein exposure significantly increased the expression of the cell cycle inhibitor 
Cdkn1a at 18 h. This indicates that direct exposure to genistein inhibits antral follicle growth by 
causing cell cycle arrest. Furthermore, I found that genistein exposure increased progesterone and 
DHEA levels, and decreased estrone and estradiol levels. The steroidogenic enzyme expression 
data indicate that genistein exposure decreased the expression of the enzyme Cyp17a1, the enzyme 
responsible for further metabolizing progesterone. Thus, explaining the observed increase in 
progesterone levels and decrease estradiol levels after exposure to genistein.  
Additionally, I hypothesized that preconception exposure to genistein affects fertility and 
pregnancy outcomes. To test this hypothesis, female mice were dosed with dietary levels of 
genistein (300, 500, or 1000 ppm) or a control diet for 30, 60, 150, or 240 days prior to mating. 
After the dosing period, animals were paired for breeding. This point on, I examined the mice for 
fertility and pregnancy endpoints, and maternal behavior. I found that after 30 days of dosing, 
genistein exposure (500 and 1000 ppm) decreased gestation time compared to control. After 60 
days of dosing, genistein exposure increased gestation time (500 and 1000 ppm), increased pup 
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mortality (500 and 1000 ppm), decreased litter size (500 ppm), and increased the average pup 
weight (500 ppm) compared to control. After 150 days of dosing, genistein exposure increased the 
number of dams with prolonged parturition (300 ppm), pup mortality (300 ppm), and poor 
maternal behavior (300 ppm). After 240 days of dosing, genistein exposure decreased fertility rates 
(300 ppm), increased pup mortality (500 ppm), and increased poor maternal behavior (500 ppm). 
Collectively, these results show that preconception exposure to dietary levels of genistein affects 
gestation time, increases parturition time, decreases litter size, increases average pup weight, 
increases pup mortality, and increases poor maternal behavior. 
Further, I hypothesized that chronic exposure to dietary levels of genistein alters steroid 
hormone levels and affect ovarian morphology in adult female mice. To test this hypothesis, mice 
were dosed with genistein (300, 500, or 1000 ppm) or a control diet for 30, 60, 150, and 240 days. 
At the end of each dosing period, mice were euthanized while in diestrus. At this time, the sera, 
ovaries, uteri and livers were weighed and collected. The sera were used to measure hormone 
levels, and the ovaries used for the histological evaluation of follicle numbers. I found that 
exposure to genistein did not significantly affect progesterone and estradiol levels at any time 
point. Genistein exposure after 30 days (300 ppm) significantly increased the number of primary 
follicles compared to control, and exposure to 500 ppm genistein increased the number of 
primordial follicles compared to control, but this change was of borderline significance. There was 
no significant change in follicle numbers after 60 days of exposure to genistein. However, mice 
exposed to genistein for 240 days, then aged to 10 months, had an increase in cystic ovaries 
compared to control. These results show that genistein exposure does not affect serum hormone 
levels, has subtle effects on follicle numbers, and increases cystic ovaries in aged mice. 
Collectively, the results of my doctoral dissertation show that exposure to genistein can adversely 
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affect antral follicle growth and function in vitro, and long term, preconception exposure to 
environmentally relevant levels of genistein adversely affects fertility and pregnancy outcomes, 
and ovarian morphology of aged mice.   
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Chapter I 
Overview 
1.1 Overview 
Genistein is an isoflavone phytoestrogen found in numerous plants and plant products such as 
lentils, chickpeas, and sunflower seeds. Although genistein is found in a number of plant products, 
humans and animals are most commonly exposed to it through the consumption of soy and soy-
derived products (1-3). This is because genistein is the predominant phytoestrogen found in 
soybeans; it accounts for two thirds of soy isoflavone content (1-3). In addition to soy 
consumption, humans are also exposed to genistein by taking phytoestrogen supplements. 
Genistein and other botanical estrogens have been used as nutraceutical compounds to prevent or 
treat a variety of medical conditions, including sexual dysfunction, depression, menopausal 
symptoms, cancer, cardiovascular disease, and kidney disease (1,4-6). Genistein also has been 
used as a chemopreventive agent in women, and as a treatment for menopausal symptoms (1,2). 
Although some studies indicate that botanical compounds such as genistein may be useful 
in treating some adverse medical conditions (1,2), the broader physiological impacts are less well 
understood. In particular, genistein exposure is a concern because it has been shown to bind to 
estrogen receptors (7) and can impact estrogen signaling pathways, such as steroidogenesis, which 
may have long-lasting adverse female health effects. Very little is known about the impact of 
botanical compounds on the ovary, the major site of estrogen receptors, steroidogenesis, and 
estradiol biosynthesis. Studies conducted on the effects of genistein on the ovary are limited and 
focus mainly on the impact of embryonic and neonatal exposures to genistein on the developing 
ovary (8-10). Such studies have shown that embryonic or neonatal exposures to genistein cause 
the development of multi-oocyte follicles, increase atresia (11), and reduce fertility in rodents (8-
10,12-15). In addition, one study indicates that exposure to genistein after weaning alters 
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circulating estradiol levels in rats, with the lower dose (10 mg/kg for three weeks) increasing 
estradiol levels and the higher dose (100 mg/kg for three weeks) inhibiting estradiol levels (16).  
Understanding the impacts of genistein on the developing and pre-pubertal ovary is 
important, but it is also critical to evaluate the effects of genistein on the adult ovary. Women are 
often exposed to genistein in their diet and as potential preventative agents and treatments for 
conditions such as menopause, cancer, and kidney disease (1). Unfortunately, epidemiological 
studies investigating the effects of botanicals, including genistein, on women’s health are scarce. 
One study suggests that consumption of a soy-based diet is associated with decreased circulating 
estradiol levels in premenopausal women (17). Of the few human studies conducted, many were 
performed in vitro using cultured human granulosa cells. Of these studies, some indicate that 
genistein exposure inhibits the estradiol biosynthesis process (18-20). Specifically, multiple 
studies have shown that genistein reduces progesterone production and estradiol levels in human 
granulosa cells (18,19), and inhibits the expression and activity of the steroidogenic enzyme 
CYP19A1 (20). Overall, these few human studies conducted show that genistein has the ability to 
affect steroidogenesis. 
The effects of genistein have also been studied in animal models. Studies have shown that 
genistein can affect folliculogenesis and steroidogenesis in rat and pig models. One such study 
shows that genistein exposure decreases the numbers of healthy primordial, primary, and pre-antral 
follicles while increasing the number of antral follicles (11). Additionally, this genistein increases 
atretic antral follicles in the rat ovaries (11). Another study indicates that genistein exposure 
increases the number of primordial follicles and decreases the number of antral follicles present in 
the ovaries of rats (12). Collectively, these studies show that genistein has the ability to affect 
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folliculogenesis in vivo, but the results often differ due to differences in rat strain, genistein dose, 
and dosing window. 
The effects of genistein on steroidogenesis have been studied extensively in vitro. Some 
studies on rat granulosa cells and porcine theca cells indicate that genistein exposure decreases 
progesterone levels (21-23). One study shows a dose dependent effect of genistein, in which lower 
doses of genistein increase progesterone levels, but higher doses decrease both progesterone and 
estradiol levels (22). To help understand the cause for changes in hormone levels, some studies 
have observed the effect of genistein on steroidogenic enzymes. One such study shows that 
treatment of genistein decreases the protein levels of CYP11A1 and gene expression of Hsd3b1, 
two key enzymes involved in the initial stages of steroidogenesis in porcine granulosa cells (24). 
Overall, these studies indicate that although the results vary, genistein is capable of altering 
steroidogenesis. 
Collectively, previous studies indicate genistein is capable of affecting normal ovarian 
development and function. These studies suggest that early life exposure to genistein affects 
follicular development in the neonatal ovary, reduces fertility, and alters sex steroid hormone 
levels in vivo (11,14). Additionally, studies conducted with granulosa and theca cells from rodents, 
humans, and pigs suggest that genistein affects steroid hormone production, and decreases 
steroidogenic enzyme gene expression, and protein levels (18-21,24,25). However, the direct 
effects of genistein on the mature, intact antral follicle, and the mechanism by which it exerts these 
effects in vitro remains unknown. Additionally, most in vivo studies focus on an early life exposure 
to high doses genistein, and only examine effects after exposure for a short period of time. Thus, 
the goals of my doctoral dissertation project were to determine if and how direct exposure to 
genistein affects the antral follicle, and to investigate the effects of a chronic exposure to 
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environmentally relevant levels of genistein on fertility outcomes, pregnancy outcomes, ovarian 
morphology, and steroid hormone production. 
To achieve these goals, I tested three main hypotheses: 1. Genistein exposure inhibits antral 
follicle growth by altering cell cycle regulators and atresia factors, resulting in altered sex steroid 
hormone production, 2. Chronic exposure to environmentally relevant levels of genistein 
negatively affects female fertility and pregnancy outcomes, and 3. Chronic exposure to 
environmentally relevant levels of genistein alters sex steroid hormone levels and affects ovarian 
morphology. To test these hypotheses, I completed the following specific aims: 
Specific Aim 1: Determine whether and how genistein exposure inhibits antral follicle growth 
and steroid hormone production in vitro. 
 To complete this aim, I isolated intact antral follicles from female CD-1 mice and cultured 
them with vehicle control (dimethyl sulfoxide; DMSO) or genistein (6.0 or 36 µM) for 18 – 96 
hours (h). Every 24 h, follicle diameters were measured to assess growth. After every time point, 
I examined the effects of genistein on the expression of apoptotic factors, cell cycle regulators, and 
steroidogenic enzymes. Additionally, I examined the effects of genistein on sex steroid hormone 
production. The data indicate that genistein exposure inhibits antral follicle growth as early as 24 
h after culture and continues to inhibit growth to 96 h in culture. The early inhibition of antral 
follicle growth is likely due to a genistein-induced increase in the expression of the cell cycle 
inhibitor cyclin-dependent kinase 1 A (Cdkn1a) at 18 h. Further, genistein exposure increased 
levels of the precursor sex steroid hormones progesterone and DHEA, but decreased estradiol and 
estrone levels. This is likely a result of genistein-induced decreased in the expression of 
cytochrome P450 17a1 (Cyp17a1), the enzyme responsible for further metabolizing progesterone 
and DHEA. These results are presented in Chapter 3. 
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Specific Aim 2: Examine the effects of chronic exposure to environmentally relevant levels 
of genistein on female fertility and pregnancy outcomes. 
 To complete this aim, I dosed female CD-1 mice (35 days) with 0, 300, 500, or 1000 ppm 
genistein for 30, 60, 150, and 240 days. Body weight and food consumption were measured twice 
a week over the course of dosing. At the end of the dosing periods, the female mice were placed 
on the control diet, and paired with a mate. To determine the effects of preconception exposure to 
genistein on fertility, I measured indices such as time to mating, mating rate, pregnancy rate, 
fertility rate, gestation time, and parturition time. To determine if genistein affected pregnancy 
outcomes, I examined pup mortality, litter size, and average pup weight. Additionally, I examined 
maternal neglect as a means of understanding pup mortality. I found that after 30 days of dosing, 
genistein exposure (500 and 1000 ppm) decreased gestation time compared to control. After 60 
days of dosing, genistein exposure increased gestation time (500 and 1000 ppm), increased pup 
mortality (500 and 1000 ppm), decreased litter size (500 ppm), and increased the average pup 
weight (500 ppm) compared to control. After 150 days of dosing, genistein exposure increased the 
number of dams with prolonged parturition (300 ppm), pup mortality (300 ppm), and poor 
maternal behavior (300 ppm). After 240 days of dosing, genistein exposure decreased fertility rates 
(300 ppm), increased pup mortality (500 ppm), and increased poor maternal behavior (500 ppm). 
These results are presented in Chapter 4.  
Specific Aim 3: Examine the effects of chronic exposure to environmentally relevant levels 
of genistein on sex steroid hormone production and ovarian morphology. 
To complete this aim, I dosed female CD-1 mice (35 days) with 0, 300, 500, or 1000 ppm genistein 
for 30, 60, 150, and 240 days. Body weight and food consumption were measured twice a week 
over the course of dosing. At the end of the dosing periods, the mice were euthanized and their 
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sera, ovaries, uteri, and livers were collected for further analyses. From this study, we determined 
that exposure to genistein exposure increases liver weight after 240 days of exposure, does not 
affect sex steroid hormone levels, increases the number of primordial and primary follicles after 
30 days of exposure, and increases the number of cystic ovaries in aged animals. These results are 
presented in Chapter 5.  
 To summarize, Chapter 1 provides an outline of my dissertation. Chapter 2 provides 
background on genistein, the ovary, and the toxic effects of genistein on the ovary. Chapter 3 
describes the results from testing the hypothesis that genistein exposure inhibits antral follicle 
growth by altering cell cycle regulators and atresia factors, resulting in altered sex steroid hormone 
production. Chapter 4 describes the results from testing the hypothesis that chronic exposure to 
environmentally relevant levels of genistein negatively affects female fertility and pregnancy 
outcomes. Chapter 5 describes the results from testing the hypothesis that chronic exposure to 
environmentally relevant levels of genistein alters sex steroid hormone levels and affects ovarian 
morphology. Finally, Chapter 6 summarizes the findings from my dissertation work and provides 
an outline for future work based on these findings.  
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Chapter 2 
Genistein, the Ovary, and Potential Endocrine Disrupting Effects 
2.1 Genistein 
 Genistein is an isoflavone phytoestrogen found in numerous plants and plant products. 
Human and animal exposure primarily occurs through the consumption of soy and soy-based 
products (1-4). This is because genistein is the predominant phytoestrogen found in soybeans; it 
accounts for two thirds of soy isoflavone content (4). In soy-based food products, genistein is 
mostly present in its unconjugated, aglycone state, but it is also found in its conjugated state when 
it is bound to a glucose molecule (4). In fact, in most unfermented soy products, genistein is 
predominantly found in its conjugated state, with only small amounts of the aglycone genistein 
present (5). Due to the fermentation process, aglycones are more abundant in fermented products 
such as miso, tempeh and soybean paste (4,6). In addition to genistein content varying by food 
product, genistein amount can also vary by soybean. Studies have shown that the isoflavone levels 
in soy beans can vary based on growing conditions, geographical location, climate, and the strain 
of the soy crop (4,6). 
 In addition to exposure from soy-based foods, humans can be exposed to genistein by 
taking phytoestrogen supplements. Recent studies indicate that numerous people consume 
phytoestrogen supplements for the prevention or treatment of a variety of ailments including 
cancer, cardiovascular health, sexual dysfunction, depression, and menopausal symptoms 
(2,3,7,8), however, the efficacy of these phytoestrogen supplements is highly debated. Since 
human exposure to genistein primarily occurs through consuming soy-based dietary products, 
exposure to genistein varies greatly. The National Health and Nutritional Examination Survey 
(NHANES) shows that the average urinary genistein concentration in a multi-ethnic, general U.S. 
population is 0.25 µM/day (9). Adults in the U.S. consuming diets rich in soy products have urinary 
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genistein concentrations ranging from 1.4 µM to 2.5 µM per day (10,11), whereas adult women in 
Japan have a higher urinary genistein concentrations range of 6.5 – 10.8 µM (4,12). This difference 
likely stems from the fact that Asian populations consume numerous soy products in their diets, 
and therefore have greater exposure than men and women in the U.S. One study examining women 
taking phytoestrogen supplements found that their average urinary genistein concentration was as 
high as 21 µM (4,11,13). Collectively, these studies show that although genistein concentration 
varies greatly by dietary choices, exposure to genistein is present in many populations.         
 Genistein, like other xenoestrogens, is a known endocrine disrupting chemical. By 
definition, an endocrine disrupting chemical (EDC) is a compound capable of mimicking, or 
altering the effects and production of endogenous steroid hormones. Studies have shown that 
genistein is capable of binding to and signaling through estrogen receptor alpha (ESR1) and 
estrogen receptor beta (ESR2), with a greater affinity for ESR 2 (14). Therefore, it is possible that 
genistein can affect estrogen signaling pathways such as steroidogenesis, which can have long-
lasting adverse effects on female health.  
 
2.2 Follicle Development in the Adult Ovary 
The adult ovary consists of different follicle types, ranging from the immature primordial 
and primary follicles to the mature pre-antral and antral follicles (15,16).The primordial follicle 
consists of a single oocyte surrounded by a layer of squamous granulosa cells (Figure 2.1). Few of 
these primordial follicles will develop into primary follicles, but many more will remain quiescent 
or undergo atresia, which is programmed cell death (15). The primary follicle consists of a single 
oocyte surrounded by a single layer of cuboidal granulosa cells (15) (Figure 2.1).Some of these 
primary follicles will then grow into pre-antral follicles. The pre-antral follicle consists of a single 
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oocyte surrounded by two or more layers of cuboidal granulosa cells and a single layer of flat theca 
cells (15) (Figure 2.1). Although many pre-antral follicles will undergo atresia, some will continue 
growing and become antral follicles. Antral follicles consist of a single oocyte surrounded by 
multiple layers of cuboidal granulosa cells, a fluid filled space known as the antrum, and two layers 
of flat theca cells (Figure 2.1).  
 The antral follicle is one of the most important follicle types in the ovary. This is because 
it is the only follicle type that can mature to ovulation and produce a viable oocyte for fertilization 
(Figure 2.1). Additionally, the antral follicle is the main follicle type responsible for ovarian sex 
steroid hormone production. The crosstalk between the theca and granulosa cells in the antral 
follicle results in the production of estradiol and its precursor hormones (15,17,18). Therefore, any 
alterations in the development or function of the antral follicle can disrupt fertility and steroid 
hormone production, resulting in infertility and numerous health problems in women.  
 
2.3 Estradiol Biosynthesis in the Adult Ovary 
The production of estradiol and its precursor hormone is a result of the crosstalk between 
antral follicle theca and granulosa cells (Figure 2.2) (17,18). The estradiol biosynthesis process 
begins with cholesterol and the protein steroidogenic acute regulatory protein (STAR). STAR is a 
transport protein responsible for regulating cholesterol transfer into the mitochondria in theca cells 
and is a rate limiting step in steroidogenesis (19,20).  In the theca cells, cholesterol is metabolized 
to pregnenolone, the required precursor hormone for progesterone, by the enzyme cytochrome 
P450 side chain cleavage (CYP11A1) (19,21). Pregnenolone can be further metabolized to two 
estradiol precursor hormones: dehydroepiandrosterone (DHEA) and progesterone (Figure 2.2). 
Metabolism of pregnenolone by the enzyme cytochrome P450 17a1 (CYP17A1) results in the 
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synthesis of DHEA (21,22). Additionally, pregnenolone can be metabolized by the enzyme 3β-
hydroxysteroid dehydrogenase 1 (HSD3B1) to produce progesterone (21-23). 
In the theca cell, both DHEA and progesterone are further metabolized by HSD3B1 and 
CYP17A1, respectively, to produce the androgen precursor hormone, androstenedione (22).  
Androstenedione can then follow one of two paths: first, it can be further metabolized by the 
enzyme 17β-hydroxysteroid dehydrogenase 1 (HSD17B1) to produce testosterone (21,24), and 
second, androstenedione can pass the basal membrane and enter the granulosa cell. Like 
androstenedione, testosterone can also pass the basal membrane and enter the granulosa cell 
(Figure 2.2) (17). In the granulosa cell, both androstenedione and testosterone are further 
metabolized to estrone and estradiol, respectively (Figure 2.2) (21). Cytochrome P450 19a1 is the 
enzyme responsible for metabolizing androgens to estrogens in the granulosa cell (18,21).  In 
addition to following the metabolic pathway to synthesize estradiol, all precursor hormones are 
capable of passing the cell membrane and circulating in the blood. 
The steroidogenic pathway is a highly regulated system that can be affected by endocrine 
disrupting chemicals by changing the expression or function of steroidogenic enzymes. Any 
alterations to the steroidogenic pathway can affect the production of sex steroid hormones and 
result in long term effects on female health and reproduction (25-29).
 
2.4 The Effects of Genistein on the Ovary and Female Reproduction 
 Genistein is a known endocrine disrupting chemical that has been shown to bind and signal 
through ESR1 and ESR2 (14). Due to its potential estrogenic function, it is crucial to study the 
effects of genistein on ovary and female reproduction. Unfortunately, current studies on the effects 
of genistein on the ovary are limited and mainly focus on the impact of embryonic and neonatal 
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exposures to genistein on the developing ovary (30-32). However, these studies indicate that 
genistein is capable of affecting ovarian development and function, and female fertility.  One study 
found that neonatal exposure to genistein (0.5, 5, and 50 mg/kg) increased the presence of multi-
oocyte follicles (MOFs) in mice (33). Another study examining the effects of neonatal exposure 
found that genistein (50 mg/kg /day) inhibits germ cell nest break down and oocyte cell death (34) 
in mice. This explains the increased presence of MOFs in genistein treated rodents. A study 
examining the pre-pubertal effects of genistein on the rat ovary found that exposure to genistein 
(50 mg/kg) decreased the number of primordial, primary and secondary follicles, while also 
increasing the number of healthy and atretic antral follicles. Collectively, these studies indicate 
that genistein adversely affects the developing rodent ovary.  
Neonatal exposure to genistein has also been found to affect female fertility outcomes later 
in life. Jefferson et al. found that neonatal exposure to relatively low doses of genistein (0.5 and 5 
mg/kg) reduced fertility as early as 6 months of age (35), and neonatal exposure to 50 mg/kg 
genistein caused complete infertility as early as 2 months of age (35). Another study found that 
neonatal exposure to genistein (100 mg/kg/day) also disrupted fertility (36). Some of these studies 
determined that some genistein-induced fertility problems were a result of defective implantation 
sites (35), but this was not always the case. These studies show that genistein affects fertility 
outcomes in neonatally exposed animals.  
Although it is important to study the effects of EDCs such as genistein on the developing 
ovary, it is equally as critical to evaluate the effects of adult exposure to genistein on the ovary and 
female fertility. Women are often exposed to genistein in their diet and as potential preventive 
agents and treatments for a variety of conditions, including cancer, neuronal loss, kidney disease, 
and menopausal symptoms (2). Unfortunately, epidemiological studies investigating the effects of 
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botanical chemicals, including genistein, on women’s health are scarce. One study suggests that 
consumption of a soy-based diet is associated with decreased circulating estradiol levels in 
premenopausal women (37).  Other studies conducted with human ovarian cells found that 
genistein exposure can affect steroidogenesis in vitro. Specifically, exposure to genistein (50 and 
100 µM) decreased the production of progesterone from pregnenolone, decreased estradiol levels, 
and altered the expression and activity of steroidogenic enzymes in human granulosa cells (38-
41). 
Interestingly, some studies using animal models suggest similar effects of genistein on 
steroidogenesis in isolated and culture ovarian follicular cells. A study conducted on cultured 
porcine theca cells found that exposure to genistein (45 µM) decreased prolactin-induced 
progesterone production (42). Studies done with rat granulosa cells have provided results that vary 
by dose. In one study, genistein exposure (0.5 - 50 µM) reduced basal levels of progesterone and 
FSH-induced progesterone levels (10 µM) (43). Another study shows that low concentrations of 
genistein (0.1 - 3 µM) increased FSH-induced progesterone levels, but high concentrations of 
genistein (30 - 100 µM) decreased FSH-induced progesterone levels (44). Genistein exposure (30 
and 100 µM) also reduced FSH-induced estradiol levels in rat granulosa cells (44). 
It is possible that some of these genistein-induced effects are a result of dysregulation of 
steroidogenic enzymes. For example, genistein exposure (10 and 50 µM) reduced the mRNA 
expression and activity of Cyp19a1 (aromatase) in human granulosa cells (40). Because aromatase 
is the key enzyme responsible for transforming precursor hormones to estradiol (Figure 2), down-
regulation of this enzyme may explain the decreased estradiol levels seen in many studies. 
Genistein exposure (1 - 50 µM) also decreased CYP11A1 protein levels and Hsd3b1 expression 
in porcine granulosa cells (45). These two enzymes are responsible for transforming cholesterol 
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and pregnenolone to progesterone (Figure 2). Thus, inhibition of these enzymes may cause the 
genistein-induced decrease in progesterone levels. Altogether, these result indicate that in vitro 
exposure to genistein affects steroid hormone levels, and expression and activity of steroidogenic 
enzymes.  
Current literature on the effects of genistein exposure show that genistein affects ovarian 
morphology and reproductive outcomes in neonatally exposed animals. Additionally, extensive in 
vitro studies indicate that genistein alters steroid hormone levels and affects the expression and 
activity of steroidogenic enzymes in human and animal cells.  However, the effects of genistein 
on intact antral follicles, one of the most important follicle types, is not well understood. In vivo, 
there is little information on the effects of an adult exposure to genistein on ovarian function, 
morphology, and female fertility outcomes. Additionally, many previous in vivo studies use doses 
of genistein that are higher than normal human or animal exposure, and only expose animals for 
short periods of time. Therefore, studies using more environmentally relevant doses of genistein 
and exposure times that more closely mimic human exposure would provide much needed 
information on the impacts of genistein on female reproductive outcomes.
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2.5 Figures  
Figure 2.1 Folliculogenesis in the adult ovary 
 
This figure represents the different follicle types present in the adult ovary. 
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Figure 2.2 Steroidogenic pathway in ovarian antral follicles 
 
 
This figure is a representation of the two cell theory of steroidogenesis in the ovarian antral 
follicle. The different sex steroid hormone are boxed. The different steroidogenic enzymes are 
placed next to an arrow to indicate their respective metabolic action. 
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CHAPTER III 
Genistein Exposure Inhibits Growth and Alters Steroidogenesis in Adult Mouse Antral 
Follicles1 
3.1 Abstract 
Genistein is a naturally occurring isoflavone phytoestrogen commonly found in plant 
products such as soybeans, lentils, and chickpeas. Genistein, like other phytoestrogens, has the 
potential to mimic, enhance, or impair the estradiol biosynthesis pathway, thereby potentially 
altering ovarian follicle growth. Previous studies have inconsistently indicated that genistein 
exposure may alter granulosa cell proliferation and hormone production, but no studies have 
examined the effects of genistein on intact antral follicles. Thus, this study was designed to test 
the hypothesis that genistein exposure inhibits follicle growth and steroidogenesis in intact antral 
follicles. To test this, antral follicles isolated from CD-1 mice were cultured with vehicle control 
(dimethyl sulfoxide; DMSO) or genistein (6.0 and 36 µM) for 18 - 96 hours (h). Every 24 h, follicle 
diameters were measured to assess growth. At the end of each culture period, the media were 
pooled to measure hormone levels, and the cultured follicles were collected to measure expression 
of cell cycle regulators and steroidogenic enzymes. The results indicate that genistein (36 µM) 
inhibits growth of mouse antral follicles. Additionally, genistein (6.0 and 36 µM) increases 
progesterone, testosterone, and dehydroepiandrosterone (DHEA) levels, but decreases estrone and 
estradiol levels. The results also indicate that genistein alters the expression of steroidogenic 
enzymes at 24, 72 and 96 h, and the expression of cell cycle regulators at 18 h. These data indicate 
that genistein exposure inhibits antral follicle growth by inhibiting the cell cycle, alters sex steroid 
hormone levels, and dysregulates steroidogenic enzymes in cultured mouse antral follicles.  
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3.2 Introduction 
Recent studies indicate that numerous people consume botanical compounds to prevent or 
treat a variety of medical conditions, including cancer, kidney disease, cardiovascular disease, 
neuronal injury, sexual dysfunction, inflammation, depression, and menopausal symptoms (1-5). 
Many botanical compounds are known phytoestrogens, plant-derived chemicals that can bind to 
and signal through estrogen receptors (1,6,7). Genistein is the predominant phytoestrogen in soy 
(Glycine max) and soy-derived products.  It accounts for two thirds of soy isoflavone content and 
has been shown to bind both estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2), 
though it is thought to have a greater affinity for ESR2 than ESR1 (1,6,7). Genistein is also a 
nutraceutical compound used as a chemo-preventive agent in women undergoing chemotherapy 
and as a treatment for menopausal symptoms (1,6).  Genistein is, therefore, considered to be one 
of the most relevant environmental estrogens in the human diet (1,8).  
Although studies indicate that botanical compounds such as genistein may be useful in 
treating some adverse medical conditions (1,6), the broader physiological impacts are less well 
understood. In particular, genistein exposure is a concern because it binds to estrogen receptors 
and can impact estrogen signaling pathways, such as steroidogenesis, which may have long-lasting 
adverse female health effects.  Very little is known about the impact of botanical compounds on 
the ovary, the major site of estrogen receptors, steroidogenesis, and estradiol biosynthesis. Proper 
functioning of the ovary, and the follicles within the ovary, are absolutely required for normal 
female fertility and estradiol biosynthesis. Further, low estradiol levels have been associated with 
reduced fertility, cardiovascular disease, mood disorders, adverse menopausal symptoms, and 
osteoporosis (9-17). Thus, botanical compounds that target the ovary have the potential to 
adversely impact overall female health. 
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Unfortunately, studies on the effects of genistein on the ovary are limited and mainly focus 
on the impact of embryonic and neonatal exposures to genistein on the developing ovary (18-20).  
Such studies have shown that embryonic or neonatal exposures to genistein cause the development 
of multi-oocyte follicles, increase atresia (21), and reduce fertility in rodents (18-20,22-25). In 
addition, one study indicates that exposure to genistein after weaning alters circulating estradiol 
levels in rats, with the lower dose (10 mg/kg for three weeks) increasing estradiol levels and the 
higher dose (100 mg/kg for three weeks) inhibiting estradiol levels (26). 
Although the impacts of genistein on the developing and pre-pubertal ovary are important, 
it is also important to evaluate the effects of botanical compounds on the adult ovary.  Women are 
often exposed to botanical compounds in their diet and as potential preventive agents and 
treatments for a variety of conditions, including cancer, neuronal loss, kidney disease, and 
menopausal symptoms (1). Unfortunately, epidemiological studies investigating the effects of 
botanicals, including genistein, on women’s health are scarce. One study suggests that 
consumption of a soy-based diet is associated with decreased circulating estradiol levels in 
premenopausal women (27). Another study indicates that genistein inhibits steroidogenesis and 
steroidogenic enzymes in cultured human luteinized granulosa cells (28-30).  Interestingly, some 
studies using animal models suggest similar effects on steroidogenesis in isolated and cultured 
ovarian follicular cells. Genistein inhibits steroidogenesis or steroidogenic enzymes in cultured rat 
pre-antral follicles (31), rat granulosa-luteal cells (32), and porcine granulosa, theca, or luteal cells 
(33-36).  Exposure to genistein also alters follicle growth (22), induces follicular atresia (26), and 
inhibits oocyte maturation (37). However, these studies have not examined the effects of genistein 
on the intact, adult antral follicle, the functional unit of the ovary. Further, they have not fully 
determined the mechanism by which genistein alters steroidogenesis in the adult ovary.  Thus, the 
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goal of these studies was to test the hypotheses that genistein inhibits 1) antral follicle growth and 
steroidogenesis in the adult mouse ovary and 2) steroidogenesis by inhibiting the levels of 
precursor hormones and the necessary steroidogenic enzymes. 
 
3.3 Materials and Methods 
Chemicals 
Genistein (98% purified via HPLC, Botanical Research Center, University of Illinois) was 
dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) then diluted in DMSO 
to achieve final treatment concentrations of 1.6 and 9.6 µg of genistein per mL of culture media 
(6.0 and 36 µM). These concentrations were selected based on previous studies using a range of 
similar doses that show that genistein affects female reproductive function (32,36,38). The 
concentrations are higher than observed in vivo after dietary consumption in rodents (39-42), but 
serve as models for the mechanistic effects of genistein on the ovary. 
 
Animals 
Adult, cycling, female CD-1 mice were purchased from Charles River (Wilmington, MA). 
The mice were housed at the University of Illinois at Urbana-Champaign, Veterinary Medicine 
Animal Facility and were provided food (Harlan Teklad 8626) and water for ad libitum 
consumption. Temperature was maintained at 22 ± 1 °C and animals were exposed to 12 hour 
light-dark cycles. The Institutional Animal Care and Use Committee at the University of Illinois 
at Urbana-Champaign approved all procedures concerning animal care, euthanasia, and tissue 
collection. 
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In vitro time-course follicle culture 
Female CD-1 mice were euthanized on postnatal days (PND) 32-35 and their ovaries 
removed using aseptic technique. Antral follicles were mechanically isolated from the ovary based 
on relative size (250-400 μm), cleaned of interstitial tissue using fine watchmaker forceps, 
individually placed in wells of a 96-well culture plate, and covered with unsupplemented α-
minimum essential media (α-MEM) prior to treatment. Follicles from 2-3 mice were isolated per 
experiment, providing approximately 20-40 antral follicles from each mouse. Each experiment 
contained a minimum of 8-12 follicles per treatment group.  
Concentrations of vehicle control (DMSO) and genistein (6.0 and 36 μM) were 
individually prepared in supplemented α-MEM. Supplemented α-MEM was prepared with the 
following: 1% ITS (10 ng/ml insulin, 5.5 ng/ml transferrin, 5.5 ng/ml selenium), 100 U/ml 
penicillin, 100 mg/ml streptomycin, 5 IU/ml human recombinant follicle-stimulating hormone 
(FSH; Dr. A. F. Parlow, National Hormone and Peptide Program, Harbor- UCLA Medical Center, 
Torrance, CA), 5% fetal calf serum (Atlanta Biologicals, Lawrenceville, GA) (43-45).Various 
stock concentrations of genistein were prepared (2.2 and 12.8 mg/mL) so that an equal volume of 
chemical could be added to each well to control for solvent concentration (0.75 μL of genistein or 
DMSO per mL of media).  
Antral follicles were cultured from 18 to 96 h in an incubator supplying 5% CO2 at 37°C. 
After each culture, follicles were pooled by treatment group and snap-frozen in liquid nitrogen and 
then subjected quantitative real time PCR (qPCR) as described below. Media were collected and 
stored at -80°C until subjected to hormone assays as described below. 
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Analysis of follicle growth 
To evaluate follicle growth over time, follicles were measured along perpendicular axes 
every 24 h for 96 h. The diameters were recorded in microns, averaged among treatments groups 
per 24 h interval, and then converted to percent change at each time-point. Percent change was 
determined by dividing the average diameters of the follicles at each 24 h interval per treatment 
group by the initial average measurement (0 h) of each respective treatment group. 
 
Analysis of hormone levels 
Media were collected from the in vitro culture system at 24 h intervals, from at least three 
separate experiments, and subjected to enzyme-linked immunosorbent assays (ELISA) for 
measurement of progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, 
estrone, and estradiol levels. ELISA kits were purchased from DRG International Inc. (Springfield, 
NJ). Assays were run according to the manufacturer’s instructions. Some samples were diluted to 
match the dynamic range of each ELISA kit. The samples were run in triplicate and had intra- and 
inter-assay coefficients of variability below 10%.  
 
Analysis of gene expression by qPCR 
Cultured antral follicles were collected at 24 h intervals and total RNA was extracted using 
the RNeasy Micro Kit (Qiagen, Inc., Valencia, CA) according to the manufacturer’s protocol. 
Reverse transcriptase generation of cDNA was performed with 0.3-0.5 μg of total RNA using an 
iScript RT kit (Bio-Rad Laboratories, Hercules CA). qPCR was conducted using the CFX96 Real-
Time PCR Detection System (Bio-Rad Laboratories, Inc.) and accompanying software (CFX 
Manager Software) according to the manufacturer’s instruction. qPCR was performed using 1 μL 
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cDNA, 1 μL of gene specific primers (Integrated DNA Technologies, Inc., Coralville, IA; Table 
3.1), 3 μL of molecular water, and 5 μL of a SsoFast EvaGreen Supermix qPCR kit (Bio-Rad 
laboratories, Hercules, CA) per sample. The qPCR program protocol was similar to that used in 
previous studies (46). A standard curve was generated from five serial dilutions of a combination 
of samples to calculate the amplification efficiency of each primer and determine relative 
expression of each target gene to the reference gene, glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh). Gapdh was used as a reference gene for each sample because its expression did not differ 
between treatment groups.  
 
Statistical analyses 
All data were analyzed using SPSS software (SPSS Chicago, IL) and expressed as mean + 
the standard error of the mean (SEM). All normally distributed data were analyzed using a one-
way analysis of variance test (ANOVA). A Dunnett’s t post-hoc test was used for the follicle 
growth and gene expression analyses, and a Tukey’s post-hoc test was used for hormone level data 
analysis. Any non-normally distributed data were analyzed using a Kruskal-Wallis test. Statistical 
significance was assigned at p ≤ 0.05, and n = 3 - 5 separate experiments. At 48 h, DHEA levels 
for the DMSO and genistein 1.6 µM groups were below the level of detection of our ELISA kits. 
Thus, to complete statistical analysis, we used the lowest detectable amount of DHEA provided 
by the kit.  
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3.4 Results 
Effect of genistein on follicle growth 
Follicles treated with vehicle control (DMSO) grew significantly over time (Figure 3.1).  
However, exposure to genistein (36 µM) significantly inhibited antral follicle growth compared to 
DMSO, beginning at 24 h and continuing throughout the 96 h culture (Figure 3.1; n=3-5, p≤0.05).  
Exposure to a lower dose of genistein (6 µM) did not significantly inhibit follicle growth compared 
to DMSO at any time point (Figure 3.1).  
 
Effect of genistein on apoptotic factors 
Since we observed inhibited growth at 24 h of culture, we examined gene expression at an 
earlier time point (18) h to see if genistein was affecting apoptotic factors to induce atresia early. 
We selected the anti-apoptotic factor B-cell lymphoma 2 (Bcl2) and the pro-apoptotic factor Bcl-
2-associated X protein (Bax) because they are important factors in regulating apoptosis in the ovary 
(47). Our data indicate that genistein does not affect the expression of the ratio of Bax to Bcl2 
(Figure 3.2), suggesting that genistein exposure at this early time point does not inhibit antral 
follicle growth by inducing atresia. 
 
Effect of genistein on cell cycle regulators 
Given that genistein does not affect growth by inducing atresia, we examined whether it 
inhibits growth by altering cell cycle regulation. Our data show that genistein significantly 
increases expression of the cell cycle inhibitor cyclin-dependent kinase inhibitor 1a (Cdkn1a) 
compared to control (Figure 3.2; n=4, p ≤ 0.05). Genistein did not affect the expression of the cell 
cycle activators cyclin A2 (Ccna2), cyclin D2 (Ccdn2), and cyclin-dependent kinase 4 (Cdk4) 
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(Figure 3.2), but it did significantly increase the expression of the cell cycle activators cyclin B1 
(Ccnb1) and cyclin E1 (Ccne1) compared to control (Figure 3.2; n=4, p ≤ 0.05).  
 
Effect of genistein on estradiol production 
Given that growing antral follicles are major producers of estradiol (48,49) and that our 
data indicate that genistein inhibits follicle growth, we next examined whether genistein affects 
the ability of antral follicles to produce estradiol.  At 24 and 48 h, genistein exposure did not 
significantly affect estradiol levels produced by antral follicles compared to controls (Figure 3).  
However, at 72 and 96 h both doses of genistein (6 and 36 µM) significantly decreased the levels 
of estradiol produced by antral follicles compared to controls (Figure 3; n= 3, p ≤ 0.05).   
 
Effect of genistein on metabolic pre-cursors to estradiol 
Production of estradiol is dependent partly on the availability of its metabolic precursors, 
estrone, testosterone, androstenedione, DHEA, and progesterone.  Thus, inhibition of these sex 
steroid hormones would indirectly inhibit production and levels of estradiol.  To test this 
possibility, we examined whether exposure to genistein alters the production of estrone, 
testosterone, androstenedione, DHEA, or progesterone by adult antral follicles. At 24 h, estrone 
levels in all treatment groups were below the level of detection of the ELISA kits (Figure 3.4). At 
48 h, genistein exposure did not affect estrone levels compared to controls. However, at 72 and 96 
h, both doses of genistein (6.0 and 36 µM) significantly decreased estrone levels compared to 
controls (Figure 3.4; n=3-5; p ≤ 0.05).  
At 24, 48, and 96 h, genistein exposure did not significantly affect testosterone levels 
compared to controls (Figure 3.5). At 72 h, both doses of genistein (6 and 36 µM) significantly 
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increased the levels of testosterone produced by antral follicles compared to controls (Figure 3.5; 
n=3; p ≤ 0.05). In contrast, genistein exposure did not significantly affect androstenedione levels 
compared to controls at any time-point (Figure 3.6).   
At 24 h, DHEA levels in all treatment groups were below the level of detection of the 
ELISA kits (Figure 3.7). However, at 48 and 72 h, genistein exposure (36 µM) significantly 
increased DHEA levels compared to control (Figure 3.7; n=3-5; p ≤ 0.05). At 96 h, both 
concentrations of genistein (6 and 36 µM) significantly increased DHEA levels compared to 
control (Figure 3.7; n=3-5; p ≤ 0.05).  
At 24 h, genistein exposure did not significantly affect progesterone levels produced by 
antral follicles compared to controls (Figure 3.8).  At 48 and 72 h, however, both doses of genistein 
(6 and 36 µM) significantly increased the levels of progesterone compared to controls (Figure 3.8; 
n=3; p ≤ 0.05).  At 96 h, only the high dose of genistein (36 µM) significantly increased the levels 
of progesterone compared to controls (Figure 3.8; n=3; p ≤ 0.05).  
 
Effect of genistein on the expression of steroidogenic enzymes 
Our data indicate that genistein increased testosterone, DHEA, and progesterone levels 
(Figures 5, 7, and 8), but decreased estradiol and estrone levels compared to control (Figures 3 and 
4), suggesting that genistein may alter the ability of antral follicles to synthesize sex steroid 
hormones. Therefore, we investigated if genistein alters the expression of the following 
steroidogenic enzymes at each time-point in the culture.  
Steroidogenic acute regulatory protein (Star) 
STAR is a transport protein responsible for regulating cholesterol transfer into the 
mitochondria and is a rate-limiting step in steroidogenesis (50,51). At 24 and 48 h, genistein did 
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not affect Star expression compared to control (Figure 3.9A). However, at 72 and 96 h, genistein 
(36 µM) significantly increased Star expression compared to controls (Figure 3.9A; n=3-5; p ≤ 
0.05).  
Cytochrome P450 side chain cleavage (Cyp11a1)  
CYP11A1 is another rate-limiting step in steroidogenesis and it is responsible for 
metabolizing cholesterol into pregnenolone, the required pre-cursor for progesterone (51,52). At 
24-72 h, genistein did not significantly alter the expression of Cyp11a1 compared to controls 
(Figure 8B). However, at 96 h, it increased the expression of Cyp11a1 compared to control (Figure 
3.9B; n=3-5; p ≤ 0.05). 
3β-hydroxysteroid dehydrogenase 1 (Hsd3b1)  
HSD3B1 is integral in metabolizing and converting Δ5-steroids (pregnenolone and DHEA) 
into Δ4-steroids (progesterone and androstenedione) (52,53). At 24 h, genistein (36 µM) decreased 
the expression of Hsd3b1 compared to controls (Figure 3.9C; n=3-5; p ≤ 0.05), but it did not affect 
expression at any other time-point (Figure 3.9C). 
Cytochrome P450 17a1 (Cyp17a1) 
CYP17A1 is important for the synthesis of DHEA and androstenedione from pregnenolone 
and progesterone, respectively (52,54). At 24 and 96 h genistein (36 µM) significantly decreased 
Cyp17a1 expression compared to controls. (Figure 3.9D; n=3-5; p ≤ 0.05), but not at 48 and 72 h.  
At 72 h, there was a trend towards decreased expression with genistein exposure (36 µM) when 
compared to controls (Figure 3.9D).  
17β-hydroxysteroid dehydrogenase 1 (Hsd17b1) 
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HSD17B1 is responsible for conversion of androstenedione to testosterone as well as 
estrone to estradiol (52,55). Genistein did not affect the expression of Hsd17b1 compared to 
controls at any time-point (Figure 3.9E; n=3-5). 
Cytochrome P450 19 (Cyp19a1) 
CYP19A1 is responsible for the conversion of androstenedione to estrone as well as 
testosterone to estradiol (52,55). Genistein did not affect the expression of Cyp19a1 compared to 
controls at any time-point (Figure 3.9F; n=3-5).  
 
Effect of genistein on the expression of estrogen receptors 
Genistein is known as an estrogenic compound and has the ability to bind and act through 
ESR1 and ESR2 (7). Thus, we examined the effect of genistein exposure on Esr1 and Esr2 
expression in antral follicles.  At 24, 72, and 96 h, genistein did not affect the expression of Esr1 
or Esr2. However, at 48h, genistein exposure increased the expression of Esr1 (6 µM) and Esr2 
(36 µM) compared to controls (Figure 3.10; n=3, p ≤ 0.05). 
 
3.5 Discussion  
Using an in vitro follicle culture system, we have shown that genistein inhibits growth of 
antral follicles, alters the expression of cell cycles regulators, disrupts the production of sex steroid 
hormones, and alters the expression of steroidogenic enzymes. Specifically, we observed that 
genistein exposure inhibits antral follicle growth as early as 24 h in culture (Figure 3.1). Our data 
are consistent with a previous in vivo  study indicating that exposure to genistein (160 mg/kg/day) 
significantly inhibits follicle growth because it increases the percentage of primordial follicles, but 
decreases the number of total antral follicles in 4 month and 15 month old rats (22). 
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To determine the cause of genistein-induced antral follicle growth inhibition, we examined 
the expression of apoptotic factors Bax and Bcl2I at 18 h of culture. We found that genistein did 
not affect apoptotic factors in antral follicles (Figure 3.2), suggesting that atresia is not the cause 
of genistein-induced antral follicles growth inhibition. Further, we observed the follicles under a 
light microscope, we noticed that the follicles appeared to be healthy, but not growing. These 
results differ from previous studies that indicate that genistein causes atresia of rat follicles. 
Medigovic et al. dosed immature female rats with 50 mg/kg/day genistein daily from postnatal 
days (PND) 18 to 20 and found decreased numbers of primordial, primary, and secondary follicles 
and increased atresia (21). Zin et al. also found that genistein treatment (10 or 100 mg/kg/day) 
from PND 22 to 42 increases atresia in Sprague-Dawley rats (26). Our results likely differ from 
these studies due differences in age as well as the doses administered. 
The observation that genistein inhibits follicle growth, but does not induce atresia led us to 
examine the effects of genistein on cell cycle regulators at 18 h. Previous studies done on other 
endocrine disruptors show that they can affect follicle growth by altering expression of cell cycle 
regulators (56,57). Our data indicate that genistein is inhibiting growth of antral follicles by 
inhibiting the cell cycle. We observed that genistein significantly increases the expression of the 
cell cycle inhibitor Cdkn1a (Figure 3.2). Although genistein also significantly increases the 
expression of the cell cycle activators Ccnb1 and Ccne1 (Figure 3.2), the change is minor in 
comparison to that of Cdkn1a, and likely a compensatory effect. This explains the inhibited growth 
of genistein treated follicles. 
Previous studies indicate that estradiol is necessary for normal follicle growth (49,58-60). 
Therefore, we initially hypothesized that genistein would inhibit antral follicle growth due to 
altered steroidogenesis. Instead, we found that genistein (36 µM) inhibits growth as early as 24 h 
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(Figure 3.1), whereas genistein does not affect estradiol levels until 72 h (Figure 3.3). Additionally, 
the lower dose of genistein (6 µM) does not affect follicle growth at any time point (Figure 3.1), 
but still decreases estradiol levels beginning at 72 h (Figure 3.3). Thereby, it is unlikely that the 
genistein-induced inhibition of growth is due to decreased levels of estradiol. Instead, it is more 
likely that inhibition of follicle growth is the cause of decreased estradiol production. 
Our data indicate that genistein exposure decreases estradiol and estrone levels in the media 
of cultured antral follicles. Estradiol and estrone are produced by converting precursor hormones 
in the theca and granulosa cells of the follicles (55). Thus, it is possible that the inhibition of antral 
follicle growth by genistein (36 µM) results in fewer granulosa cells being present in the follicle 
to produce estradiol. This is supported by our data indicating that genistein exposure (36 µM) 
inhibits antral follicle growth first at 24 h (Figure 3.1), whereas it inhibits estradiol levels beginning 
at 72 h (6 and 36 µM) (Figure 3.3). Another likely scenario is that genistein is affecting the 
metabolism of estradiol and estrone. It is possible that genistein increases estradiol and estrone 
metabolism by inducing cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1). 
Thus, future studies should determine whether genistein affects estradiol metabolism by inducing 
CYP1A1 and CYP1B1. Additionally, our data indicate that genistein exposure increases the 
expression of Esr1 (6 µM) and Esr2 (36 µM) (Figure 3.10). It is possible that this genistein-induced 
increase could lead to greater responsiveness of antral follicles to genistein and further result in 
decreased production of estradiol.     
Our data on the effects of genistein on estradiol levels are consistent with several, but not 
all previous studies.  Specifically, we showed that genistein exposure reduced estradiol production 
from cultured antral follicles.  Similarly, dietary genistein exposure decreased estradiol levels in 
male mice (8 mg/kg; (61)), cultured swine granulosa cells (185 µM; (33)), and Sprague Dawley 
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rats (10 and 100 mg/kg/day; (26)).  Additionally, daily consumption of soy products containing 
genistein reduced circulating levels of estradiol over the menstrual cycle in nine healthy regularly 
cycling women (27).  Further, acute (4 h) and chronic (24 h) genistein exposure inhibited estradiol 
production in cultured, luteinized human granulosa cells (30). In contrast, neonatal genistein 
exposure (50 mg/kg/day) did not affect serum levels of estradiol when measured before puberty or 
during pregnancy in female mice (24).  Further, genistein did not affect FSH-stimulated estradiol 
production in cultured porcine (0.5-50 µM; (35)) or immature rat granulosa cells (1-10 µM; (31)). 
The reasons for these differences in results pertaining to the effects of genistein on estradiol levels 
are unclear, but likely stem from differences in species (mice versus rats, humans, and pigs), and 
study design (doses of genistein, timing of treatment, age of animals, and in vivo versus in vitro 
methods).  It is also possible that our in vitro results differ from other in vitro studies because we 
used an antral follicle culture system, which consists of the intact functional units of the ovary. 
Other studies used isolated granulosa cells (31,35), which normally produce sex steroid hormones 
in conjunction with theca cells and, thus, may behave differently alone compared to intact antral 
follicles.   
Our data indicate that genistein exposure also alters the levels of other precursor hormones 
(Figures 4-8). Specifically, we observed that genistein exposure increases testosterone, DHEA, 
and progesterone levels compared to control (Figures 5, 7, and 8). Similar to our results, one study 
indicates that genistein exposure (10-10,000 ng/mL) increases progesterone release by bovine 
granulosa cells and rabbit granulosa cells (100-10,000 ng/mL) (62). Additionally, genistein 
exposure (0.1-3 µM) increases FSH-induced progesterone levels in rat granulosa cells (63). This 
same study, however, shows that higher concentrations of genistein (30-100 µM) decrease FSH-
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induced progesterone levels (63), thereby indicating dose related differences in the effects of 
genistein on steroidogenesis. 
Our findings on the effects of genistein on progesterone and testosterone differ from other 
previously conducted studies. One study indicates that neonatal genistein exposure (50 mg/kg/day) 
does not affect serum levels of progesterone or testosterone when measured before puberty and 
during pregnancy in mice (24). Additionally, genistein exposure (1, 18.5, and 185 µM) inhibits 
FSH-stimulated and basal progesterone levels in cultured porcine granulosa cells (33,35)), LH-
stimulated progesterone secretion in porcine luteinized granulosa cells (0.5-50 µM; (64)), and 
prolactin-stimulated progesterone secretion in porcine thecal cells (45 µM; (36)). Furthermore, 
genistein exposure (50 µM) inhibits the ability of primary porcine granulosa cells to produce 
progesterone (34). Genistein exposure (1-100 µM) also decreases progesterone levels in human 
granulosa cells (28,30). It is likely that our results differ from previous studies largely due to 
species differences in the effects of genistein on sex steroid hormone levels.  Most previous studies 
were conducted with pigs (33-36,64) or human cells (28,30), whereas our study was conducted in 
mice. Further, our results likely differ from the other study conducted in mice (24) because of the 
differences in study design, such as in vitro vs in vivo experiments and pre-pubertal vs adult, non-
pregnant exposure timing, as well as the differences in genistein concentrations. Traditional 
toxicology dogma indicates that endocrine disrupting chemicals can have differing effects across 
a range of concentrations and that low dose effects may be different than those observed at higher 
doses (65). 
Adequate estradiol biosynthesis is dependent on the availability of upstream precursor 
hormones and steroidogenic enzymes.  In the estradiol biosynthesis pathway, StAR transports 
cholesterol from the outer membrane to the inner membrane of the mitochondria (50,51).  
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Cholesterol then is converted to pregnenolone by CYP11A1 (52).  Pregnenolone is then converted 
to estradiol via two pathways.  In the first pathway, pregnenolone is converted to DHEA by 
CYP17A1 (54).  DHEA is then converted to androstenedione by HSD3B1 (53,55).  
Androstenedione is converted to either estrone by CYP19A1 or testosterone by HSD17B1 (52,55). 
Finally, testosterone is converted to estradiol via CYP19A1 (52,55).  In the second pathway, 
pregnenolone is converted to progesterone by HSD3B1 (53).  The progesterone is converted to 
androstenedione by CYP17A1 (54), then testosterone, and finally estradiol (52,55).  
Although the mechanism by which genistein alters testosterone and DHEA, remains 
unknown, our steroidogenic enzyme findings shed some light on why we observe a genistein-
induced increase in progesterone levels. We observed a genistein-induced decrease in Cyp17a1 as 
early as 24 h and it continued until 96 h (Figure 3.9D). Because CYPA17A1 is the enzyme 
responsible for progesterone metabolism, a decrease in its expression would decrease progesterone 
metabolism. Further, beginning at 72 h, we observed an increase in Star and Cyp11a1 expression 
(Figures 9A and 9B), two enzymes that increase progesterone production. Collectively, the 
decrease in progesterone metabolism and increase in progesterone production led to unusually high 
levels of progesterone in response to genistein. 
In conclusion, our results indicate that genistein exposure inhibits the growth of mouse 
antral follicles in vitro, likely by inhibiting the cell cycle. Our results also indicate that estradiol, a 
key factor involved in the growth of antral follicles, is significantly decreased in genistein-treated 
follicles compared to control. Additionally, our results show that genistein alters the levels of the 
estradiol precursor hormones estrone, testosterone, DHEA, and progesterone. Finally, our data 
indicate that genistein induces dysregulation of steroidogenic enzyme expression and this may be 
the cause of genistein-induced altered hormone levels in cultured mouse antral follicles. This 
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study, as well as future ones that further elucidate how genistein alters steroidogenic enzymes and 
steroid hormone production, are important because genistein-induced altered hormone levels and 
inhibition of antral follicle growth could lead to numerous health risks and female infertility. Many 
people, both men and women, are exposed to genistein and other phytoestrogen-based botanicals 
regularly as part of their diet or as therapeutics for reproductive and non-reproductive diseases. 
Therefore, it is imperative to understand how genistein and other botanicals may impact overall 
public health.
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3.6 Figures and Table 
Table 3.1 Primers used in quantitative real-time polymerase chain reactions (qPCR)  
Specific primer sequences used for qPCR analysis of gene expression 
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Figure 3.1 Effect of genistein on follicle growth over time 
 
After isolation, antral follicle growth was measured daily along perpendicular axes and percent 
change in growth was determined from 24 to 96 h. The graph represents the means ± SEM of 
percent change in follicle growth from 3 separate experiments. Asterisks (*) indicate a significant 
difference between control groups and genistein at each time point (n=3; p≤ 0.05).
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Figure 3.2 Effects of genistein on apoptotic factors and cell cycle regulators at 18h 
 
After culture of antral follicles for 18 h, follicles were collected and subjected to RNA extraction. 
The RNA was reverse transcribed to cDNA and used to measure gene expression of Bax, Bcl2, 
Cdkn1a, Ccna2, Ccnb1, Ccnd2, Ccne1, and Cdk4 by quantitative polymerase chain reaction 
(qPCR). Asterisks (*) indicate a significant difference between control groups and genistein at 
each time point (n=4; p≤ 0.05).
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Figure 3.3 Effects of genistein on estradiol production over time 
 
After culture of antral follicles for 24-96 h, media were collected and subjected to enzyme-linked immunosorbent assays for estradiol. 
The graph represents the means ± SEM from 3 separate experiments. Asterisks (*) indicate a significant difference between control 
groups and genistein at each time point (n=3; p≤ 0.05).
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Figure 3.4 Effects of genistein on estrone production over time 
 
After culture of antral follicles for 24-96 h, media were collected and subjected to enzyme-linked immunosorbent assays for estrone. 
The graph represents the means ± SEM from 3-5 separate experiments. Asterisks (*) indicate a significant difference between control 
groups and genistein at each time point (n=3-5; p≤ 0.05).
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Figure 3.5 Effects of genistein on testosterone production over time 
 
After culture of antral follicles for 24-96 h, media were collected and subjected to enzyme-linked immunosorbent assays for testosterone. 
The graph represents the means ± SEM from 3 separate experiments. Asterisks (*) indicate a significant difference between control 
groups and genistein at each time point (n=3; p≤ 0.05).
47 
 
Figure 3.6 Effects of genistein on androstenedione production over time 
 
After culture of antral follicles for 24-96 h, media were collected and subjected to enzyme-linked immunosorbent assays for 
androstenedione. The graph represents the means ± SEM from 3 separate experiments.
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Figure 3.7 Effects of genistein exposure on DHEA production over time 
 
After culture of antral follicles for 24-96 h, media were collected and subjected to enzyme-linked immunosorbent assays for DHEA. 
The graph represents the means ± SEM from 3-5 separate experiments. Asterisks (*) indicate a significant difference between control 
groups and genistein at each time point (n=3-5; p≤ 0.05).
49 
 
Figure 3.8 Effects of genistein on progesterone production over time 
 
After culture of antral follicles for 24-96 h, media were collected and subjected to enzyme-linked immunosorbent assays for 
progesterone. The graph represents the means ± SEM from 3 separate experiments. Asterisks (*) indicate a significant difference 
between control groups and genistein at each time point (n=3; p≤ 0.05). 
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Figure 3.9 Effects of genistein on the gene expression of steroidogenic enzymes over time 
 
After culture of antral follicles for 24-96 h, follicles were collected and subjected to RNA 
extraction. The RNA was reverse transcribed to cDNA and used to measure gene expression of 
key steroidogenic enzymes by qPCR. Asterisks (*) indicate a significant difference between 
control groups and genistein at each time point (n=3-5; p≤ 0.05).
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Figure 3.10 Effects of genistein on the gene expression of Esr1 and Esr2 
After culture of antral follicles for 24-96 h, follicles were collected and subjected to RNA 
extraction. The RNA was reverse transcribed to cDNA and used to measure gene expression of 
Esr1 and Esr2 by qPCR. Asterisks (*) indicate a significant difference between control groups and 
genistein at each time point (n=3-5; p≤ 0.05).
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CHAPTER IV 
The Effects of Exposure to Dietary Levels of Genistein on Female Fertility and Pregnancy 
Outcomes 
4.1 Abstract 
Genistein is a phytoestrogen commonly found in plants such as soy beans and chickpeas. 
Humans and animals are most commonly exposed to genistein through consumption soy and soy-
based dietary products. Genistein is a known endocrine disrupting chemical, and previously, we 
determined that genistein is capable of decreasing estradiol levels and inhibiting the growth of 
antral follicles in vitro. Proper hormone production and follicle growth are both key factors for 
normal fertility. Therefore, we hypothesized that dietary levels of genistein negatively affect 
female fertility and pregnancy outcomes. To test this hypothesis, we dosed female CD-1 mice (35 
days) with 0, 300, 500, or 1000 ppm genistein for 30, 60, 150, and 240 days. The doses of genistein 
were selected because they result in serum genistein levels similar to those observed in humans 
after genistein exposure (1-3 µM). Body weight and food consumption were measured twice a 
week over the course of dosing. At the end of the dosing periods, the female mice were placed on 
the control diet, and paired with a mate. To determine the effects of preconception exposure to 
genistein on fertility, we measured indices such as time to mating, mating rate, pregnancy rate, 
fertility rate, gestation time, and parturition time. To determine if genistein affected pregnancy 
outcomes, we examined pup mortality, litter size, and average pup weight. Additionally, we 
examined maternal neglect as a means of understanding pup mortality. We found that after 30 days 
of dosing, genistein exposure (500 and 1000 ppm) decreased gestation time compared to control. 
After 60 days of dosing, genistein exposure increased gestation time (500 and 1000 ppm), 
increased pup mortality (500 and 1000 ppm), decreased litter size (500 ppm), and increased the 
average pup weight (500 ppm) compared to control. After 150 days of dosing, genistein exposure 
increased the number of dams with prolonged parturition (300 ppm), pup mortality (300 ppm), and 
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poor maternal behavior (300 ppm). After 240 days of dosing, genistein exposure decreased fertility 
rates (300 ppm), increased pup mortality (500 ppm), and increased poor maternal behavior (500 
ppm). Collectively, these results show that preconception exposure to dietary levels of genistein 
affects gestation time, increases parturition time, decreases litter size, increases average pup 
weight, increases pup mortality, and increases poor maternal behavior.  
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4.2 Introduction 
 Genistein is an isoflavone phytoestrogen commonly found in plants and plant based 
products. Genistein is the predominant phytoestrogen in soy (Glycine max) and soy-derived 
products; it accounts for two thirds of soy isoflavone content (1). Therefore, human and animal 
exposure to genistein occurs primarily through the consumption of soy and soy-based dietary 
products (1). Exposure to genistein can also occur from taking dietary soy supplements (1). Recent 
studies indicate that numerous people consume soy dietary supplements for the prevention or 
treatment of a variety of ailments, including cancer, cardiovascular health, sexual dysfunction, and 
depression (1-5).    
Although a few studies indicate that botanical compounds such as genistein may be useful 
in treating some adverse medical conditions (3,5), the broader physiological impacts are less 
understood. Genistein exposure is of particular concern in regards to female health and fertility. 
This is because genistein, similar to other xenoestrogens, can bind and signal through estrogen 
receptors (6); thereby impacting estrogen signaling pathways and resulting in long-lasting, adverse 
female health effects. Studies have shown that exposure to environmental estrogens affects female 
fertility in numerous species (7-9). Most current studies examine the effects of an early life 
exposure to genistein on female fertility. These studies show that embryonic or neonatal exposures 
to genistein cause multi-oocyte follicle development, increase atresia in follicles (10), reduce 
fertility, and cause premature reproductive senescence (11-17) in rodents.  
Understanding the impacts of genistein on the developing and pre-pubertal ovary is 
important; however, it is equally as critical to evaluate the effects of adult exposure to genistein 
on fertility and the ovary. Women are often exposed to genistein in their diet and as potential 
preventive agents and treatments for a variety of conditions, including cancer, neuronal loss, 
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kidney disease, and menopausal symptoms (3). Unfortunately, epidemiological studies 
investigating the effects of botanical chemicals, including genistein, on women’s health are scarce. 
One study suggests that consumption of a soy-based diet is associated with decreased circulating 
estradiol levels in premenopausal women (18). Other studies have examined at the effects of 
genistein on cultured human luteinized granulosa cells and found that exposure to genistein inhibits 
steroidogenesis (19-21). 
Interestingly, studies conducted using animal models suggest that genistein has similar 
effects on steroidogenesis in isolated and cultured ovarian follicle cells. Specifically, genistein 
inhibits steroidogenesis or steroidogenic enzymes in cultured rat pre-antral follicles (22), rat 
granulosa-luteal cells (23), porcine granulosa, theca, or luteal cells (24-27), and mouse antral 
follicles (28). Additionally, studies have shown that genistein exposure alters follicle growth (17), 
induces follicular atresia (29), inhibits oocyte maturation (30), and inhibits antral follicle growth 
(28) in rodents. Collectively, these studies show that genistein exposure can affect hormone levels 
and follicle growth, both of which are necessary for normal female fertility (31).  
Although these studies document adverse effects of genistein exposure on key factors of 
fertility, they do not show direct effects of genistein on female fertility. Additionally, many of 
these studies examine the effects of a short-term exposure to high doses of genistein, whereas low 
dose exposure over a longer period is more relevant to human and animal exposure. Therefore, 
this study was designed to test the hypothesis that long-term exposure to dietary levels of genistein 
reduces fertility in female mice.  
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4.3 Materials and Methods 
Chemicals and diet formulation 
Genistein (98% purified via HPLC, Botanical Research Center, University of Illinois) was 
sent to Enivgo-Teklad (Madison, WI) to formulate custom diets. We used the AIN-93G (Envigo-
Teklad, Madison, WI), phytoestrogen free diet as our control and base diet. For the genistein 
treated diet, 300, 500, and 1000 parts per million (ppm) genistein were added to our base diet. 
Mice consuming these doses of genistein have been found to have serum genistein levels of 1, 1.8, 
and 2.6 µM (32). These serum levels are within the range of those observed after human exposure. 
 
Animals 
Female CD-1 (30 days) mice were purchased from Charles River Laboratories 
(Wilmington, MA) and were allowed to acclimate to the facility prior to dosing. The mice were 
housed four per cage at the University of Illinois at Urbana Champaign, Veterinary Medicine 
Animal Facility and were provided food and water ad libitum. Temperature was maintained at 22 
± 1 ºC and animals were exposed to 12-hour light and dark cycles. 
 
Study design 
Beginning on postnatal day (PND) 35, female CD-1 mice were fed diets containing 0, 300, 
500, or 1000 ppm genistein ad libitum for 30, 60, 150, or 240 days. All mice and food were 
weighed and recorded twice a week to ensure all the animals were eating similar amounts of food 
and that there were no abnormal changes to their weights. Change in weight and amount of food 
consumed were analyzed at 30, 60, 150, and 240 days. At the end of the week, remaining food was 
weighed and subtracted from the amount of food given to the mice. This gave us an average amount 
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of food consumed in a week. To calculate daily average food consumption, the weekly average 
was divided by the number of days between feeding and the last day of the week.  At each time 
point, 6 female mice from each treatment group were paired with an untreated male for breeding. 
At the time of pairing, all mice were placed on the control diet, and remained on the control diet 
for the remainder of the experiment. 
 
Estrous cyclicity  
To evaluate changes in estrous cyclicity, we examined vaginal smears from all the mice 
for 10 days prior to the 30, 60, 150, and 240 days of dosing time points. The percentage of time 
the mice spent in each stage was calculated and reported.  
 
Mating, pregnancy, fertility, and gestational indices 
To examine the effects of exposure to dietary levels of genistein on female fertility, we 
analyzed the following factors: 1) time to mating: the number of days between pairing and the 
presence of a vaginal sperm plug, indicating successful mating; 2) mating rate: number of females 
observed with vaginal sperm plugs / number of breeding pairs x 100; 3) pregnancy rate: number 
of females who became pregnant/ number of breeding pairs x 100, where pregnancy was confirmed 
by weight gain over time; 4) fertility rate: number of females that became pregnant/ number of 
females plugged x 100; 5) gestation time: the length of time between presence of a vaginal sperm 
plug and the day of birth; and 6) prolonged parturition: the percentage of dams that gave birth for 
longer than one day.  
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Pregnancy outcomes and maternal behavior and neglect 
To examine the effects of exposure to dietary levels of genistein on pregnancy outcomes, 
we analyzed the following factors: 1) dams with some pups dead, meaning the dam lost more than 
1, but not all of her pups; 2) dams with all pups dead; and 3) average litter size, and Average pup 
weight.  
To examine maternal behavior, we scored for moderate and severe neglect based on 
methods previously published by Catanese et al. (33). Moderate neglect was indicated by poor 
cleaning of pups and/or poor nesting, possibly resulting in some pup loss. Severe neglect was 
indicated by lack of nesting and nursing, trampling of pups, and usually resulted in complete 
infanticide. We also compared the incidence of pup death in cases in which we did not observe 
any neglectful behavior.  
 
Statistical analyses 
 Data were statistically analyzed using the SPSS software (IBM, Chicago, IL). A one-way 
ANOVA was used to determine significant changes between groups with significance determined 
p≤0.05. If the ANOVA was significant, we used a Dunnett’s 2 sided t-test to determine which 
treatment group was significantly different from the control. Pup mortality and maternal neglect 
were analyzed using a Fisher’s exact test  
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4.4 Results 
Change in body weight over lifetime 
We examined the change in body weight twice a week over the lifetime of each animal. 
We found that there was no significant change in weight in the genistein treated animals compared 
to control at any time point (Figure 4.1; n=10-48). 
 
Food consumption over lifetime 
To determine if animals were eating similar amounts of food during the course of the study, 
we measured the amount of food consumed twice a week over their lifetime. We found that there 
were no significant changes in the amount of food consumed by the genistein treated animals at 
any time point compared to control (Figure 4.2; n=10-48) 
 
Estrous cyclicity 
We examined estrous cyclicity of all mice 10 days prior to the 30, 60, 150, and 240 day 
collection time points. We did not observe any significant differences in the percent of time spent 
in any of the phases of the estrous cycle in the genistein-treated animals compared to control 
(Figure 4.3; n=10-48). 
 
Fertility outcomes 
At the end of each dosing time point, animals were paired with a mate for breeding. 
Beginning at this point, we measured the time to mating, mating rate, pregnancy rate, fertility rate, 
gestation time, and the number of dams presenting with prolonged parturition. We found no 
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significant differences in the time to mating in the genistein treated animals when compared to 
control at any time point (Table 4.1).  
Similarly, we did not observe in differences in the mating rate after 30, 60, or 240 days of 
dosing in the genistein-treated animals compared to control (Table 4.1). However, after 150 days 
of dosing, the 500 ppm genistein group had a decreased mating rate (only 83% of dams 
successfully mated with a male) compared to control (Table 4.1; n=6).  
We did not observe any difference in the pregnancy rate after 30 or 60 days of dosing in 
the genistein treated groups compared to control (Table 4.1). However, after 150 days of dosing, 
both the 500 and 1000 ppm genistein groups had a decreased mating rate compared to control. In 
both the 500 and 1000 ppm groups, only 83% of dams became pregnant (Table 4.1; n=6). After 
240 days of dosing, we observed a natural decline in the pregnancy rate of the control mice. 
Additionally, we observed a similar decline in the  pregnancy rate of the 300 and 500 ppm genistein 
groups, but not in the 1000 ppm genistein group (Table 4.1; n=6).  Specifically, only 67% of the 
dams in the control group became pregnant, only 50% of the dams became pregnant in the 300 
ppm genistein group, and only 83% of the dams in the 500 ppm genistein group became pregnant, 
whereas 100% of the animals in the 1000 ppm genistein group became pregnant (Table 4.1; n=6). 
After 30 and 60 days of dosing, we did not observe any differences in the fertility rate in 
any treatment groups (Table 4.1). However, after 150 days of dosing, both the 500 and 1000 ppm 
genistein groups had decreased fertility rates compared to control (Table 4.1; n=6). In both groups, 
only 83% of dams became pregnant after successfully mating with a male. After 240 days of 
dosing, we observed a natural decline in the fertility rate of the control mice. A similar decline was 
observed in fertility rate of the mice in the 300 and 500 ppm genistein group. Specifically, after 
successfully mating with a male, 67% of the dams in control group, 50% of the dams in the 300 
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ppm genistein group, and 83% of the dams in the 500 ppm genistein group were fertile, whereas 
100% of the dams in the1000 ppm genistein group were fertile (Table 4.1; n=6). 
Next, we examined gestation time at each time point. After 30 days of dosing, we observed 
significantly decreased gestation time in the 500 and 1000 ppm genistein groups compared to 
control (Table 4.1; n=6, p≤0.05). After 60 days of dosing, we observed an increased gestation time 
in the 500 and 1000 ppm genistein groups compared to control, but this was not statistically 
significant (Table 4.1; n=6). After 150 days and 240 days of dosing, we did not observe any 
differences in the gestation time in any of the treatment groups when compared to control (Table 
4.1; n=6).  
We also examined the number of dams that presented with prolonged parturition at each 
time point. After 30 and 60 days of dosing, we did not observe any dams having prolonged 
parturition. However, after 150 days of days of dosing, we observed 1 dam in the control group, 4 
dams in the 300 ppm group, and 2 dams in 1000 ppm group with prolonged parturition (Table 4.1; 
n=6). After 240 days of dosing, we did not observe prolonged parturition in the control and 500 
ppm groups. However, in the 300 ppm group, 1 out of the 3 dams that became pregnant had a 
prolonged parturition (Table 4.1; n=6). Additionally, after 240 days of dosing, 1 dam from the 
1000 ppm group displayed prolonged parturition (Table 4.1; n=6). 
 
Pregnancy outcomes and litter data 
After birth, we examined pregnancy and litter outcomes to determine the survival and 
health of the pups. After 30 days of dosing, we found that in the control group, 1 dam lost her 
entire litter. Further, the 300 ppm group had 1 dam that lost some of her pups, and the 1000 ppm 
group had 1 dam that lost her entire litter (Table 4.2; n=6). After 60 days of dosing, none of the 
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dams in the control and 300 ppm groups experienced pup mortality. However, 2 dams from both 
the 500 and 1000 ppm groups lost some of their pups (Table 4.2; n=6).  
After 150 days of dosing, in the control group, 1 dam lost some of her pups and 2 dams 
lost their entire litter, and in the 300 ppm group, 1 dam lost some of her pups and 3 dams lost their 
entire litter (Table 4.2; n=6). In the 500 ppm group and 1000 ppm groups, 1 dam from each group 
lost some of her pups (Table 4.2; n=5). After 240 days of dosing, 1 of the 3 dams in the control 
group lost some pups from her litter (Table 4.2; n=3). In the 300 ppm group, none of the dams 
experienced pup mortality. In the 500 ppm group, 1 of the 5 dams lost some pups, and the 
remaining 4 dams lost their entire litters (Table 4.2; n=5). In the 1000 ppm group, 2 out of 5 dams 
lost some of their pups, and 1 of the 5 dams lost their entire litter (Table 4.2; n=5). Using a Fisher’s 
test, we determined that there was a significant difference in pup mortality based on treatment 
group (Table 4.2; p=0.03, n=3-5). 
Next, we analyzed average litter size and pup weight. After 30 days of dosing, we did not 
observe any significant differences in the average litter size or pup weight in any treatment group 
compared to control (Table 4.2; n=6). After 60 days of dosing, we observed a significant decrease 
in litter size in the 500 ppm group compared to control (Table 4.2; n=6, p≤0.05). Additionally, 
after 60 days of dosing, we observed a significant increase in average pup weight in the 500 ppm 
group when compared to control (Table 4.2; n=6, p≤0.05). After 150 days of dosing, we observed 
a decrease in average litter size in the 500 and 1000 ppm groups, however, this was not statistically 
significant (Table 4.2; n=6). We did not observe any differences in the average pup size in any of 
the groups when compared to control. After 240 days of dosing, we did not observe any differences 
in average litter or pup weight when compared to control (Table 4.2; n=3-6). 
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Maternal neglect 
Upon seeing an increase in pup mortality after 150 and 240 days of dosing, we scored 
maternal neglect. After 150 days of dosing, we observed that 1 dam from the control group 
displayed severe maternal neglect behaviors. Further, 3 dams in the 300 ppm group displayed 
maternal neglect (Table 4.3; n=6). No maternal neglect was observed in the 500 and 1000 ppm 
groups. After dosing for 240 days, we observed no maternal neglect behaviors in the control or 
300 ppm groups (Table 4.3; n=3). However, 1 of the 5 dams from the 500 ppm group displayed 
moderate maternal neglect, and 3 of the 5 dams from the 500 ppm group displayed severe maternal 
neglect (Table 4.3; p=0.06, n=5). In the 1000 ppm group, 1 of the 5 dams displayed maternal 
neglect (Table 4.3; n=5). We determined that there is a difference in maternal neglect based on 
treatment group, and that this effect was of borderline significance (Table 4.3; p=0.06, n=3-5). 
 
4.5 Discussion 
 Our study examined the effects of chronic exposure to dietary levels of genistein on female 
fertility and pregnancy outcomes. Our results show that exposure to genistein (500 and 1000 ppm) 
for 30 days significantly decreased gestation time compared to control. Further, exposure to 
genistein for 60 days increased gestation time (500 and 1000 ppm), increased pup mortality (500 
ppm), decreased litter size (500 ppm) and increased average pup weight (500 ppm). In addition, 
genistein exposure for 150 days increased the number of dams with prolonged parturition (300 
ppm), pup mortality (300 ppm), and poor maternal behavior (300 ppm). Exposure to genistein for 
240 days at 300 ppm genistein decreased fertility rates, whereas exposure to genistein at 1000 ppm 
maintained fertility. Additionally, exposure to 500 ppm genistein for 240 days increased pup 
mortality and poor maternal behavior. Collectively, these results provide new insight on how 
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preconception exposure to dietary levels of genistein affects numerous fertility and pregnancy 
outcomes.  
 In current literature, there is a lack of information on the effects of adult exposure to 
genistein on fertility outcomes. However, some studies have examined the effects of neonatal 
genistein exposure on fertility outcomes. One such study has shown that exposure to 
environmentally relevant levels of genistein can affect female fertility in mice. Specifically, 
Jefferson et al. found that neonatal exposure to genistein (0.5 and 5 mg/kg/day) significantly 
decreased the number of dams producing live pups at 6 months, and that exposure to 50 mg/kg/day 
genistein decreased the number of dams with live pups born as early as 2 months of age (11). From 
these results, the authors concluded that neonatal genistein exposure causes early reproductive 
senescence. Similar to Jefferson et al., we observed altered fertility rates in our study. However, 
Jefferson et al. appeared to have a linear dose dependent decrease in fertility, whereas we observed 
different effects at different doses. Specifically, after 240 days of dosing, we observed a natural 
decline in fertility rate of the control group (67% fertile). In comparison, the 300 ppm group had 
reduced fertility rate (50%), whereas the 500 and 1000 ppm had greater fertility rates (83% and 
100%, respectively) than control. This would indicate that perhaps relatively higher doses of 
genistein have a protective effect on fertility later in life. The difference between our fertility 
results and the ones observed by Jefferson et al. likely stem from the drastically different exposure 
windows. However, despite having different results, both our study and the one conducted by 
Jefferson et al. clearly indicate that exposure to environmentally relevant doses of genistein affects 
fertility outcomes in female mice. 
  One of the earliest effects that we observed in our study was genistein-induced change to 
the gestation time. We observed that exposure to genistein (500 and 1000 ppm) significantly 
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decreased gestation time after 30 days of exposure (Table 4.1; n=6, p≤0.05), and increased 
gestation time after 60 days of exposure, but this change was of borderline significance (Table 4.1; 
n=6, p=0.07). This phenomenon has not been reported in previous studies conducted with neonatal 
genistein exposure, or in studies that examined the effects of adult exposure to other endocrine 
disruptors. However, a study examining the effects of altered estrogen receptor (ER) expression 
found a similar effect in their mice. They observed that 68% of the ER over-expressing mice (3-5 
months old) had increased gestation time (34). In the same study, Davis et al. found that the ER 
over-expressing mice also had prolonged labor, with some animals giving birth over the course of 
three days (34). Similarly, in our study, we observed a genistein-induced increase in prolonged 
parturition. Specifically, we observed that 4 of the 6 animals dosed with genistein (300 ppm) for 
150 days took 2-3 days to complete giving birth (Table 4.1). Due to changes in gestation and 
parturition times similar to those seen by Davis et al., we could presume that in our study, genistein 
may be altering the expression of ER in mice treated with genistein for 30, 60, and 150 days. It 
would be ideal to examine the expression of ER in the ovary and the uterus in future studies. 
 In addition to effects on gestation and parturition, we observed a genistein-induced 
decrease in litter size. After 60 days of dosing, we observed that genistein exposure (500 ppm) 
significantly decreased the average litter size and increased the average pup weight compared to 
control (Table 4.1; n=6, p≤0.05). After 150 days of dosing, we again observed a decrease in 
average litter size in genistein treated dams (500 and 1000 ppm), however, this change was not 
statistically significant. Most studies examining the effects of genistein have not found significant 
changes in litter size (1), however, Jefferson et al. also observed a decrease in litter size (11). It is 
possible that in both instances, the observed decrease in litter size is an indicator of early 
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reproductive senescence. Previous studies have shown that the reproductive aging involves gradual 
changes, including smaller litter size (35,36), similar to what we observed in our study. 
 Another genistein-induced effect that we observed on pregnancy outcomes was an increase 
in pup mortality. After 240 days of dosing, exposure to genistein increased the presence of pup 
mortality (500 and 1000 ppm), and increased the severity of it, as indicated by the 4 out of 5 dams 
exposed to 500 ppm genistein that lost their entire litters. 
Although we observed increased pup mortality, the effects occurred at different doses, and 
the means by which pup mortality occurred also varied. However, consistently the pups were born 
alive at all doses. Although no other studies on genistein reported reasons for pup mortality, a 
study examining the effects of the endocrine disruptor bisphenol S (BPS) found that exposure to 
BPS increased poor maternal behavior (33). Thus, we examined whether genistein exposure 
caused pup mortality through a mechanism involving maternal neglect.  To determine poor 
maternal behavior, we examined maternal traits and scored for neglect as described by Catanese 
et al. (33). We observed that at the 150 day time point, 3 out of 6 dams treated with genistein (300 
ppm) portrayed neglectful maternal behavior. Additionally, we determined that the dams that 
displayed poor maternal behavior and experienced pup mortality were also the dams that 
experienced prolonged parturition. These dams were not able to take the time to clean off their 
pups and properly nest and nurse because they were in labor for 2-3 days, resulting in their pups 
not being cleaned, and not receiving warmth or food needed for survival. When analyzing maternal 
neglect in the dams dosed with genistein for 240 day, we observed an effect on maternal neglect 
based on treatment group that was borderline significant (Fisher’s test p=0.06). After 240 days of 
dosing, we observed that 4 out of 5 dams in the 500 ppm genistein treated group displayed poor 
maternal behavior. Specifically, we observed that the dams that lost their entire litters initially 
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cleaned off their pups and created proper nests, but by PND 2 the dams had killed and eaten parts 
of all their litters. The cause of this infanticide is unknown, however, it is possible that this effect 
is a result of genistein exposure affecting the onset of maternal care in first time mothers. 
Previously, it has been shown that CD-1 female mice need only a short sensitization period to pups 
before the onset of maternal care, regardless of whether they gave birth to the pups (37), after 
which dams will begin to care for the pups. Therefore, if genistein is delaying the onset of maternal 
behavior, it is possible that the dams would neglect their pups. When examining maternal behavior 
in the animals treated with 1000 ppm genistein for 240 days, we found that only 1 out of 5 dams 
displayed maternal neglect. Therefore, the cause of pup mortality in this dose group remains 
unknown.  
 Collectively, this study provides new information on the effects of long term, 
preconception exposure to dietary levels of genistein on female fertility and pregnancy outcomes. 
Dosing animals through their diet, for longer time periods, and using environmentally relevant 
doses allowed us to more closely mimic human and animal exposure to genistein. The results from 
this study indicate that even at doses obtainable through dietary exposure, genistein is capable of 
having effects on female fertility. Although exposure to genistein was stopped at the time of 
mating, preconception exposure can impact pregnancy outcomes such as gestation time, parturition 
time, litter size, pup weight, pup mortality, and maternal behavior. Future studies should be 
conducted to examine the underlying mechanism by which the 500 ppm genistein group decreases 
litter size. Additionally, future studies should examine whether exposure to genistein (1000 ppm) 
maintains the protective effect on fertility.
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4.6 Figures and Tables 
Figure 4.1 Change in body weight over lifetime 
 
At each time point, body weight of all mice was measured and compared to starting weights to 
determine the change in body weight over time. The graph represents the means ± standard error 
of the means (SEM) of change in body weight of surviving mice at each time point (n=10-48).
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Figure 4.2 Average daily food consumption over lifetime   
 
Daily average food consumption was calculated to monitor if all animals were consuming similar 
amounts of food. The graph represents the means ± SEM of daily food consumption over the 
course of the study (n=12-48).
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Figure 4.3 Estrous cyclicity  
 
Estrous cyclicity was monitored for ten days prior to each collection time point. The graphs 
represent the means ± SEM number of days spent in each phase of the cycle: D/M being the 
combined number of days spend in diestrus and metestrus, P for proestrus, and E for estrus. 
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Table 4.1 Effect of genistein on female fertility outcomes 
 
Fertility outcomes were measure at each time point. Time to mating is expressed as the means ± 
SEM of the number of days between paring and presence of a vaginal sperm plug. The mating, 
pregnancy, and fertility rates are expressed as a percentage of the number dams in each treatment 
group. Gestation time is expressed as the means ± SEM of the number of gestational days. 
Prolonged parturition is expressed as a ratio of the number dams presenting with prolonged 
parturition and the total number of pregnant dams in each treatment group. Asterisks (*) represent 
a statistically significant difference from the control (n=6, p≤0.05). Arrows (^) indicate a 
borderline significant effects (n=6, p=0.07). Pound sign (#) indicates a difference in the total 
number of dams from the number of breeding pairs. 
30 Days # Breeding Pairs Time to Mating Mating rate Pregnancy Rate Fertility Rate Gestation Time (days) Prolonged Parturition
Control 6 2.33 ± 0.67 100 100 100 19.00 ± 0.00 0/6
300 ppm 6 2.75 ± 0.25 100 100 100 18.50 ± 0.29 0/6
500 ppm 6 2.67 ± 0.25 100 100 100 18.00  ± 0.00 * 0/6
1000 ppm 6 2.40 ± 0.40 100 100 100 18.20  ± 0.20 * 0/6
60 Days # Breeding Pairs Time to Mating Mating rate Pregnancy Rate Fertility Rate Gestation Time (days) Prolonged Parturition
Control 6 2.8 ± 0.49 100 100 100 19.33  ± 0.33 0/6
300 ppm 6 3.33 ± 0.21 100 100 100 19.40  ± 0.55 0/6
500 ppm 6 2.67 ± 0.33 100 100 100 20.20  ± 0.45 ^ 0/6
1000 ppm 6 3.00 ± 0.00 100 100 100 20.00  ± 0.00 ^ 0/6
150 Days # Breeding Pairs Time to Mating Mating rate Pregnancy Rate Fertility Rate Gestation Time (days) Prolonged Parturition
Control 6 2.17 ± 0.54 100 100 100 19.00  ± 0.00 1/6
300 ppm 6 2.17 ± 0.41 100 100 100 18.83  ± 0.17 4/6
500 ppm 6 2.40 ± 0.24 83 83 83 19.25  ± 0.25 0/6
1000 ppm 6 2.80 ± 0.49 100 83 83 19.25  ± 0.25 2/6
240 Days # Breeding Pairs Time to Mating Mating rate Pregnancy Rate Fertility Rate Gestation Time (days) Prolonged Parturition
Control 6 2.83 0.40 100 67 67 19.50 ± 0.29 0/6
300 ppm 6 3.40 ± 1.21 100 50 50 20.50 ± 1.50 1/3 #
500 ppm 6 3.17 ± 0.70 100 83 83 19.40 ± 0.24 0/6
1000 ppm 6 2.67 ± 0.21 100 100 100 19.20 ± 0.17 1/6
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Table 4.2 Effects of genistein on pregnancy outcomes   
 
Pregnancy outcomes and litter data were analyzed at every time point. Dams with some and all 
pups dead are expressed as a ratio of the number of dams presenting some or all dead pups versus 
the number of pregnant dams in each group. Litter size is expressed as the means ± SEM of the 
litter sizes of each dam in each group at each time point. The average pup weight is expressed as 
the means ± SEM of the average pup weight from each litter in each group at each time point. 
Asterisks (*) represent a statistically significant difference from the control (p≤0.05). Pound signs 
(#) indicate a difference in the total number of dams used in the analyses from the total number of 
pregnant dams.
30 Days # Dams Dams With Some Pups Dead Dams With All Pups Dead Litter Size Average Pup Weight
Control 6 0/6 1/6 11.67  ± 0.67 1.64  ± 0.02
300 ppm 6 1/6 0/6 11.83  ± 0.79 1.57  ± 0.08
500 ppm 6 0/6 0/6 11.67  ± 0.84 1.57  ± 0.05
1000 ppm 6 0/6 1/6 11.83  ± 0.95 1.62  ± 0.05
60 Days # Dams Dams With Some Pups Dead Dams With All Pups Dead Litter Size Average Pup Weight
Control 6 0/6 0/6 11.80  ± 0.66 1.50  ±0.02
300 ppm 6 0/6 0/6 11.00  ± 1.14 1.69  ± 0.07
500 ppm 6 2/6 0/6 9.20  ± 1.32 * 1.91  ± 0.14 *
1000 ppm 6 2/6 0/6 11.33  ± 0.61 1.66  ± 0.06
150 Days # Dams Dams With Some Pups Dead Dams With All Pups Dead Litter Size Average Pup Weight
Control 6 1/6 2/6 11.80  ± 1.01 1.63  ± 0.04
300 ppm 6 1/6 3/6 10.00  ± 1.76 1.53  ± 0.06
500 ppm 5 1/5 0/5 9.80  ± 2.03 1.59  ± 0.10
1000 ppm 5 1/5 0/5 8.80  ± 1.56 1.76  ± 0.11
240 Days # Dams Dams With Some Pups Dead Dams With All Pups Dead Litter Size Average Pup Weight
Control 4 1/3 # 0/3 8.50 ± 2.75 1.65 ± 0.12
300 ppm 3 0/3 0/3 10.33 ± 0.88 1.70 ± 0.06
500 ppm 5 0/5 4/5 9.80 ± 1.02 1.54 ± 0.08
1000 ppm 6 2/5 # 1/5 # 8.17 ± 0.87 1.58 ± 0.03
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Table 4.3 Maternal behavior and pup mortality 
 
Maternal behavior was assessed to examine the presence of neglectful maternal behavior. 
Moderate and severe maternal neglect are expressed as a ratio of number of dams with neglectful 
behavior versus the total number of pregnant dams. Pup death is represented as a ratio of the 
number of dams that experienced pup death versus the total number of pregnant dams. Arrows (^) 
indicate a borderline significant change compared to control (n=3-5, p=0.06).  
 
150 Days # Dams Moderate Maternal Neglect Severe Maternal Neglect Pup Death but No Neglect
Control 6 0/6 1/6 2/6
300 ppm 6 0/6 3/6 1/6
500 ppm 6 0/6 0/6 1/6
1000 ppm 6 0/6 0/6 1/6
240 Days # Dams Moderate Maternal Neglect Severe Maternal Neglect Pup Death but No Neglect
Control 3 0/3 0/3 1/3
300 ppm 3 0/3 0/3 0/3
500 ppm 5 1/5 ^ 3/5 ^ 1/5
1000 ppm 5 0/5 1/5 2/5
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CHAPTER V 
The Effects of Exposure to Environmentally Relevant Levels of Genistein on Sex Steroid 
Hormone Production and Ovarian Morphology 
5.1 Abstract 
Genistein is phytoestrogen commonly found in plants such as soy beans. Human and 
animal exposure occurs primarily through the consumption of soy and soy-based dietary products. 
Genistein, like other phytoestrogens, has the potential to mimic, enhance, or impair the estradiol 
biosynthesis pathway, and is therefore categorized as an endocrine disrupting chemical. Altering 
the estradiol biosynthesis pathway can lead to altered follicular development in the ovary. Some 
previous studies have indicated that exposure to genistein may alter hormone production and 
follicular growth in vitro, but no studies have examined the effects of chronic exposure to 
environmentally relevant doses of genistein on steroid hormone levels and follicular development 
in the adult ovary. Thus, this study was designed to test the hypothesis that chronic exposure to 
dietary levels of genistein alters steroid hormone levels and affect ovarian morphology in adult 
female mice. To test this hypothesis, we dosed female CD-1 mice (35 days) with 0, 300, 500, or 
1000 ppm genistein for 30, 60, 150, and 240 days. The doses of genistein were selected because 
they result in serum genistein levels similar to those observed in humans after genistein exposure 
(1-3 µM). Body weight and food consumption were measured twice a week over the course of 
dosing. At the end of the dosing periods, the mice were euthanized and their sera, ovaries, uteri, 
and livers were collected for further analyses. From this study, we determined that exposure to 
genistein exposure has subtle effects on ovarian follicle numbers, but increases the number of 
cystic ovaries in aged animals.  
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5.2 Introduction 
 Genistein is a phytoestrogen commonly found in plants such as soy beans. Humans and 
animals are primarily exposed to genistein through the consumption of soy and soy-based dietary 
products. Recent studies indicate that many women consume dietary soy supplements, which 
contain genistein, to treat a variety of medical conditions, including cancer, kidney disease, 
cardiovascular disease, sexual dysfunction, depression, and menopausal symptoms. Although 
some studies indicate that botanical estrogens such as genistein may be useful in treating some 
adverse medical conditions (1,2), the broader physiological symptoms are less well understood. 
Like other xenoestrogens, genistein is capable of binding and signaling through estrogen receptors. 
In fact, previous studies have found that genistein binds to both estrogen receptor alpha (ESR1) 
and estrogen receptor beta (ESR2), with a greater binding affinity to ESR2 (1-3). Due to its 
estrogenic structure and ability to bind to estrogen receptors, genistein can impact estrogen 
signaling pathways, such as steroidogenesis. This can result in long-lasting adverse female health 
effects. The effects of genistein on the ovary are of particular concern, because the ovary is a major 
site of estrogen receptors and estradiol biosynthesis. However, very little is known about the 
impact of botanical estrogens such as genistein on the ovary.  Proper hormone production and 
follicle development within the ovary are key factors for normal female fertility (4) and overall 
female health (5-10). Therefore, it is important to examine the effects of genistein on estradiol 
biosynthesis and proper follicular development.  
Current studies examining the effects of genistein on the ovary are limited and mainly focus 
on the effects of short term, embryonic and neonatal exposure to genistein on the developing ovary 
(11-13).  Overall, these studies demonstrate genistein-induced effects on follicular development 
and estradiol biosynthesis in animal models. Specifically, these studies have found that early life 
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exposure to genistein inhibits germ cell nest breakdown, increases the development of multi-
oocyte follicles, increases follicular atresia, and reduces fertility in rodents (11-18). Additionally, 
previous work indicates that acute, post-weaning exposure to 10 mg/kg genistein increases 
circulating estradiol levels in rats, whereas exposure to 100 mg/kg inhibits estradiol levels (19).  
Although the impacts of genistein on the developing and pre-pubertal ovary are important, 
it is also crucial to evaluate the effects of botanical estrogens on the adult ovary. This is because 
women are often exposed to botanical compounds in their diets and as supplements to potentially 
prevent or treat a variety of conditions including cancer, kidney disease, menopausal symptoms, 
and depression (1). Epidemiological studies are scarce, but one such study suggests that 
consumption of a soy-based diet is associated with decreased circulating estradiol levels in 
premenopausal women (20). However, a few studies have been conducted in vitro using cultured 
human luteinized granulosa cells, and the results indicate the genistein exposure inhibits 
steroidogenesis and steroidogenic enzymes (21-24). 
Interestingly, studies using animal cells suggest similar effects on steroidogenesis in 
isolated and cultured ovarian follicular cells. These studies have found that genistein exposure 
inhibits steroidogenesis or steroidogenic enzymes in cultured rat pre-antral follicles (25), rat 
granulosa-luteal cells (26), porcine granulosa, theca, or luteal cells (27-30), and cultured mouse 
antral follicles (31).  Exposure to genistein also alters follicle growth in rats (16), induces follicular 
atresia in rats (19), inhibits oocyte maturation in mice (32), and inhibits growth of cultured mouse 
antral follicles (31). Collectively, these studies indicate that adult exposure to genistein can affect 
follicle development and steroidogenesis in the adult ovary. However, many of the previous studies 
were conducted in vitro, used doses of genistein that are much higher than normal human or animal 
exposure, and involved short-term exposure. Therefore, our study was designed to closely mimic 
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the exposure route and length of exposure time observed in humans and animals, and to determine 
if this environmentally relevant exposure to genistein alters follicle development and estradiol 
biosynthesis in adult mice. 
  
5.3 Materials and Methods 
Chemicals and diet formulation 
Genistein (98% purified via HPLC, Botanical Research Center, University of Illinois) was 
sent to Envigo-Teklad (Madison, WI) to formulate custom diets. We used the AIN-93G (Envigo-
Teklad, Madison, WI), phytoestrogen free diet as our control and base diet. For the genistein 
treated diet, 300, 500, and 1000 parts per million (ppm) genistein were added to our base diet. 
Mice consuming these doses of genistein have been found to have serum genistein levels of 1, 1.8, 
and 2.6 µM (33). These serum levels are within the range of those observed after human exposure. 
 
Animals 
Female CD-1 (30 days) mice were purchased from Charles River Laboratories 
(Wilmington, MA) and allowed to acclimate to the facility prior to dosing. The mice were housed 
four per cage at the University of Illinois at Urbana Champaign, Veterinary Medicine Animal 
Facility and were provided food and water ad libitum. Temperature was maintained at 22 ± 1 ºC 
and animals were exposed to 12-hour light and dark cycles. 
 
Study design 
Beginning at PND 35, female CD-1 mice were fed diets containing 0, 300, 500, or 1000 
ppm genistein ad libitum for 30, 60, 150, or 240 days. All mice and food were weighed and 
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recorded twice a week to ensure all the animals were eating similar amounts of food and that there 
were no abnormal changes to their weights. Changes in body weight and amount of food consumed 
were analyzed at 30, 60, 150, and 240 days. After each exposure period, 6 female mice from each 
treatment group were euthanized when in diestrus, and tissues were collected for further analysis.  
 
Body and organ weight analyses 
At the end of each dosing period, body weights from all of the mice in each treatment group 
were recorded. Further, mice were euthanized in diestrus, and the ovaries, uterus, and liver of each 
mouse were aseptically removed, cleaned of fat and interstitial tissues, and weighed. Organ 
weights were recorded in grams (g).  
 
Measurement of serum estradiol and progesterone levels 
Following exposure to genistein for 30, 60, 150, or 240 days, mice were euthanized during 
diestrus. Blood was drawn from the mice immediately following euthanasia. The collected blood 
was centrifuged and the separated serum was subjected to enzyme-linked immunosorbent assays 
(ELISAs) for the measurement of estradiol and progesterone levels. ELISA kits were purchased 
from DRG International Inc. (Springfield, NJ), and were run according to the manufacturer’s 
instructions. Samples were run in duplicate and had intra- and inter-assay coefficients of variability 
below 10%.  
 
Assessment of ovarian morphology 
After euthanasia, one ovary from each animal was fixed in Dietrich’s solution for 
histological evaluation. The fixed ovaries were transferred to 70% ethanol, embedded in paraffin 
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wax, and serial sectioned (8 µm) using a microtome. The serial sections were mounted on glass 
slides and stained with hematoxylin and eosin. Follicle numbers were counted in every tenth 
section using previously defined criteria (34-37). Briefly, primordial follicles contained an oocyte 
surrounded by a single layer of squamous granulosa cells, primary follicles contained an oocyte 
surrounded by a single layer of cuboidal granulosa cells, pre-antral follicles contained an oocyte 
surrounded by at least two layers of cuboidal granulosa cells and theca cells, and antral follicles 
contained an oocyte surrounded by multiple layers of cuboidal granulosa cells with a fluid filled 
antral space and theca cells. All primordial and primary follicles were counted in each section 
regardless of nuclear material in the oocyte, whereas only pre-antral and antral follicles containing 
nuclear material in the oocyte were counted to avoid double counting the larger follicle types that 
can span multiple sections. Follicles transitioning between stages were counted as follicles within 
the more immature stage of the two stages. Follicles were considered unhealthy if they showed 
numerous apoptotic granulosa cells or oocyte abnormalities. All other follicles were considered 
morphologically healthy. 
 
Assessment of aged ovaries 
After 240 days of exposure, 6 animals from each treatment group were placed on a control 
diet and paired with a mate for breeding. After the dams gave birth, we waited until the dams were 
around 10 months of age and euthanized them and collected their ovaries to examine if there were 
any signs of early aging on the ovary.  
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Statistical analyses 
Data were analyzed using SPSS software (SPSS Chicago, IL) and expressed as mean ±the 
standard error of the mean (SEM). Normality of distribution of the data was determined using a 
Shapiro-Wilke test. All data were normally distributed and therefore, analyzed using a one-way 
analysis of variance text (ANOVA). If the ANOVA was significant, a Dunnett’s 2-sided post-hoc 
test was used to determine significant difference between each of the treatment groups and the 
control. Statistical significance was assigned at p ≤ 0.05, n = 3-6 samples per treatment group. 
 
5.4 Results 
Body and organ weight at collections  
We measured the body weight of all surviving animals at each collection time point, and 
found that there were no significant differences in body weight in the genistein treated animals 
compared the control at any time points (Figure 5.1; n=10-48). 
Further, we found no significant changes in ovary and uterine weights in the genistein treated mice 
compared to control at any time point (Table 5.1; n=4-6). Additionally, we found no changes in 
liver weights in genistein treated mice compared to controls after 30, 60, and 150 days of dosing 
(Table 5.1; n=4-6). However, after 240 days, we found that exposure to 500 ppm genistein 
significantly decreased liver weight when compared to control (Table 5.1; n=6, p=0.036). 
 
Serum estradiol and progesterone  
We did not observe any significant changes in serum estradiol levels in any genistein 
treated groups compared to controls at any time point (Figure 5.2; n=4-6). Additionally, we did 
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not observe any significant changes in serum progesterone levels in any genistein treated groups 
compared to controls at any time point (Figure 5.2; n=4-6). 
 
Ovarian follicle morphology 
After 30 days of dosing, exposure to 300 ppm genistein significantly increased the number 
of primary follicles in the ovary compared to control (Figure 5.3; n=3, p=0.047). However, 
exposure to 300 ppm genistein did not significantly change the number primordial, preantral, antral 
and total follicles present compared to control (Figure 5.3; n=3). Exposure to 500 ppm genistein 
increased the number of primordial follicles compared to control, however this change was of 
borderline significance (Figure 5.3; n=3, p=0.08). Exposure to 500 ppm genistein did not alter any 
other follicle type or total follicle numbers compared to control (Figure 5.3, n=3). Exposure to 
1000 ppm genistein did not change the numbers of any follicle type present in the ovary or the 
total number of follicle compared to control (Figure 5.3, n=3). After 60 days dosing, we did not 
observe any statistically significant differences in the follicle numbers of genistein treated ovaries 
compared to control (Figure 5.4, n=3).  
 
Presence of cystic ovaries 
Ovaries from female mice treated with genistein for 240 days were collected when the mice 
were 10 months of age and assessed for the presence of cystic ovaries. We observed that 0% of 
control dams had cystic ovaries, whereas 50% of dams treated with 300 ppm genistein presented 
with cystic ovaries (Table 5.2; p=0.09, n=6). Additionally, 33% of dams treated with 500 ppm 
genistein and 17% of dams treated with 1000 ppm genistein presented with cystic ovaries (Table 
5.2; n=5-6). 
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5.5 Discussion 
Genistein is considered to be one of the most relevant environmental estrogens in the 
human diet due to its abundant presence in soy and the increased use of genistein as a nutraceutical 
compound for the treatment of some ailments (1,38).  However the broader physiological effects 
of genistein are unknown. Specifically, there is a lack of information on the effects of chronic 
exposure to environmentally relevant genistein doses on hormone production and follicular 
development in the adult ovary. Therefore, we tested the effects of long-term exposure to dietary 
levels of genistein on sex steroid levels and ovarian morphology in the adult mouse. Overall, we 
found that exposure to genistein does not appear to have significant effects on body weight serum 
estradiol, and serum progesterone levels. In contrast, exposure to genistein for 30 days increased 
the number primordial follicles (500 ppm) present compared to control (Figure 5.3; n=3, p=0.08), 
and significantly increased the number of primary follicles (300 ppm) compared to control (Figure 
5.3; n=3, p=0.047). However, after 60 days of dosing, there were no significant changes in ovarian 
follicle numbers when compared to control (Figure 5.4). Additionally, we found an increase in 
cystic ovaries in 10 month old mice that were dosed with dosed of genistein for 240 days (Table 
5.2; n=6).   
Contrary to our results, numerous in vitro studies conducted on adult ovarian cells show 
that exposure to genistein reduces estradiol biosynthesis and alters progesterone production 
(23,24,30,31,39). One major difference between our study and the previous in vitro studies is the 
dose selection. All previous in vitro studies directly exposed the ovarian cells to very high doses 
of genistein (30-100 µM). In contrast, the doses of genistein in our study (300, 500, 1000 ppm) 
result in serum genistein levels of 1, 1.8, and 2.6 µM, respectively (33). It is very likely that the 
doses used in our study are too low to have any direct effects on hormone production. Another 
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possibility is that the doses from our study are having subtle effects on hormone production, which 
could not be detected with the sample size in our study. 
After 30 days of dosing, we observed that exposure to 500 ppm genistein increased the 
number of primordial follicles (Figure 5.3; n= 3 p=0.08), and exposure to 300 ppm genistein 
significantly increased the number of primary follicles (Figure 5.3; n=3, p=0.047) compared to 
control. Additionally, exposure to genistein (300 and 500 ppm) increased the number of total 
follicles in the ovary compared to control. However, this change is not statistically significant due 
to the large amount of variability. It is possible that with a larger sample size this change may 
become significant. It is important to acknowledge this increase in total numbers because after 60 
days of dosing, it again appears that exposure to genistein (300 and 500 ppm) increases the total 
follicle numbers. Again, this change is not statistically significant; however, it is possible that with 
a larger sample size it may be significant. Additionally, because we observed this trend after 30 
and 60 days of dosing with genistein, it is possible that it will occur after 150 and 240 days of 
dosing.  Thus, future studies should examine genistein treated ovaries after 150 and 240 days of 
dosing.  
After 240 days of dosing with genistein, female mice were aged to 10 months before their 
ovaries were collected. At this point, we observed a dose dependent increase in the presence of 
cystic ovaries. Our lowest dose of genistein (300 ppm) resulted in the highest percentage of cystic 
ovaries (50% of dams), whereas only 17% of dams treated with our highest dose of genistein (1000 
ppm) had cystic ovaries, and no dams from the control group had cystic ovaries (Table 5.2). 
Previous studies have found that elevated luteinizing hormone (LH) levels have been associated 
with the formation of cystic ovarian follicles (40). Therefore, future studies should analyze serum 
LH levels. Additionally, it has been previously shown that older mice have increased levels of 
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serum LH compared to younger mice (41). Therefore, it is possible that the increase in cystic 
ovaries in genistein treated mice is a result of genistein-induced early reproductive aging.   
Although the results from our study indicate that exposure to genistein has subtle effects 
on ovarian follicle numbers after 30 and 60 days of dosing, the observed increase in cystic ovaries 
after 240 days of dosing leads us to conclude that low levels of genistein can affect ovarian 
morphology over time. Future studies should examine ovarian morphology immediately after 150 
and 240 days of dosing to determine what changes are occurring that lead to cystic ovaries later in 
life. Collectively, the results from this study give us a better understanding of the effects of chronic 
exposure to environmentally relevant levels of genistein.
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5.6 Figures and Tables  
 
Figure 5.1 Body weight over lifetime 
 
Body weight of all surviving animals was recorded at each time point. This graph is represented 
as the means ± the SEM of the average body weight of all the mice in each treatment group at each 
time point (n= 10-48). 
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Table 5.1 Organ weights 
  
 
This table contains the average wet weight of the ovaries, uteri, and livers collected from the 
animals from each treatment group at every time. The weights are represented as the means ± SEM 
of the organ weight at time of collection (n=4-6).  Asterisk (*) indicates a statistically significant 
change compared to control (n=4-6, p≤0.05).
30 days 60 days 150 days 240 days
Ovary weight
Control 0.016 ± 0.002 0.019 ± 0.002 0.024 ± 0.002 0.027 ± 0.005
300 ppm 0.015 ± 0.002 0.016 ± 0.002 0.023 ± 0.002 0.021 ± 0.004
500 ppm 0.015 ± 0.001 0.017 ± 0.001 0.023 ± 0.005 0.021 ± 0.003
1000 ppm 0.016 ± 0.001 0.020 ± 0.002 0.018 ± 0.003 0.020 ± 0.002
Uterine weight
Control 0.095 ± 0.007 0.100 ± 0.008 0.137 ± 0.016 0.175 ± 0.029
300 ppm 0.085 ± 0.009 0.118 ± 0.013 0.159 ± 0.072 0.134 ± 0.020
500 ppm 0.118 ± 0.018 0.100 ± 0.007 0.097 ± 0.005 0.184 ± 0.028
1000 ppm 0.121 ± 0.021 0.112 ± 0.086 0.133 ± 0.085 0.188 ± 0.052
Liver weight
Control 1.10 ± 0.04 1.38 ± 0.05 1.49 ± 0.13 1.78 ± 0.05
300 ppm 1.07 ± 0.05 1.20 ± 0.07 1.50 ± 0.08 1.61 ± 0.06
500 ppm 1.09 ± 0.05 1.32 ± 0.04 1.20 ± 0.13 1.44 ± 0.11 *
1000 ppm 1.16 ± 0.07 1.33 ± 0.10 1.36 ± 0.02 1.69 ± 0.11
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Figure 5.2 Serum estradiol and progesterone levels 
Serum collected from animals in diestrus was subjected to ELISAs for the measurement of 
estradiol and progesterone levels. These graphs represent the means ± SEM of serum estradiol and 
progesterone levels from animals collected at each time point (n=4-6). 
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Figure 5.3 Ovarian follicle numbers after 30 days of genistein exposure 
 
This graph represents that number of each follicle type and the total follicle numbers in each 
treatment group. The data are represented as means ± SEM of the follicle number from each 
treatment group. Arrow (^) indicates a change that is borderline statistically significant compared 
to control (n=3, p=0.08). Asterisk (*) indicates a statistically significant change compared to 
control (n=3, p≤0.05)
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Figure 5.4 Ovarian follicle numbers after 60 days of genistein exposure 
 
This graph represents the number of follicles present after 60 days of dosing with genistein. The 
data are represented as means ± SEM of the follicle number from each treatment group (n=3). 
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Table 5.2 Ovarian cysts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This table represents the percent of mice that had cystic ovaries after being dosed with genistein 
for 240 days, then being allowed to become pregnant, give birth, and nurse their pups (n=6). The 
arrow indicates a change that is borderline statistically significant compared to control (n=6, 
p=0.09)   
% Cysts
Control 0
300 ppm 50
500 ppm 33
1000 ppm 17
^ 
99 
 
5.7 References 
 
1. Khan SI, Zhao J, Khan IA, Walker LA, Dasmahapatra AK. Potential utility of natural 
products as regulators of breast cancer-associated aromatase promoters. Reprod Biol 
Endocrinol 2011; 9:91 
2. Yoon K, Kwack SJ, Kim HS, Lee BM. Estrogenic endocrine-disrupting chemicals: 
molecular mechanisms of actions on putative human diseases. J Toxicol Environ Health B 
Crit Rev 2014; 17:127-174 
3. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. 
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen 
receptors alpha and beta. Endocrinology 1997; 138:863-870 
4. Hirshfield AN. Development of follicles in the mammalian ovary. Int Rev Cytol 1991; 
124:43-101 
5. Bagur AC, Mautalen CA. Risk for developing osteoporosis in untreated premature 
menopause. Calcif Tissue Int 1992; 51:4-7 
6. Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol 1998; 
8:229-235 
7. Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, Rosner B, 
Stampfer MJ. Age at natural menopause and risk of cardiovascular disease. Arch Intern 
Med 1999; 159:1061-1066 
8. Christiansen C. Prevention and treatment of osteoporosis with hormone replacement 
therapy. Int J Fertil Menopausal Stud 1993; 38 Suppl 1:45-54 
9. Mosca L. Estrogen and atherosclerosis. J Investig Med 1998; 46:381-386 
10. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler 
HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in 
women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 
1987; 75:1102-1109 
11. Jefferson WN, Doerge D, Padilla-Banks E, Woodling KA, Kissling GE, Newbold R. Oral 
exposure to genistin, the glycosylated form of genistein, during neonatal life adversely 
affects the female reproductive system. Environmental health perspectives 2009; 
117:1883-1889 
12. Jefferson WN, Padilla-Banks E, Newbold RR. Disruption of the female reproductive 
system by the phytoestrogen genistein. Reproductive toxicology (Elmsford, NY) 2007; 
23:308-316 
13. Chen Y, Jefferson WN, Newbold RR, Padilla-Banks E, Pepling ME. Estradiol, 
progesterone, and genistein inhibit oocyte nest breakdown and primordial follicle assembly 
in the neonatal mouse ovary in vitro and in vivo. Endocrinology 2007; 148:3580-3590 
100 
 
14. Jefferson WN, Padilla-Banks E, Newbold RR. Adverse effects on female development and 
reproduction in CD-1 mice following neonatal exposure to the phytoestrogen genistein at 
environmentally relevant doses. Biology of reproduction 2005; 73:798-806 
15. Medigovic I, Ristic N, Trifunovic S, Manojlovic-Stojanoski M, Milosevic V, Zikic D, 
Nestorovic N. Genistein affects ovarian folliculogenesis: a stereological study. Microsc 
Res Tech 2012; 75:1691-1699 
16. Zhuang XL, Fu YC, Xu JJ, Kong XX, Chen ZG, Luo LL. Effects of genistein on ovarian 
follicular development and ovarian life span in rats. Fitoterapia 2010; 81:998-1002 
17. Britt KL, Simpson ER, Findlay JK. Effects of phytoestrogens on the ovarian and pituitary 
phenotypes of estrogen-deficient female aromatase knockout mice. Menopause 2005; 
12:174-185 
18. Cimafranca MA, Davila J, Ekman GC, Andrews RN, Neese SL, Peretz J, Woodling KA, 
Helferich WG, Sarkar J, Flaws JA, Schantz SL, Doerge DR, Cooke PS. Acute and chronic 
effects of oral genistein administration in neonatal mice. Biology of reproduction 2010; 
83:114-121 
19. Zin SR, Omar SZ, Khan NL, Musameh NI, Das S, Kassim NM. Effects of the 
phytoestrogen genistein on the development of the reproductive system of Sprague Dawley 
rats. Clinics (Sao Paulo) 2013; 68:253-262 
20. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of an isoflavone-free soy diet on 
ovarian hormones in premenopausal women. J Clin Endocrinol Metab 2001; 86:3045-3052 
21. Lacey M, Bohday J, Fonseka SM, Ullah AI, Whitehead SA. Dose-response effects of 
phytoestrogens on the activity and expression of 3beta-hydroxysteroid dehydrogenase and 
aromatase in human granulosa-luteal cells. The Journal of steroid biochemistry and 
molecular biology 2005; 96:279-286 
22. Rice S, Mason HD, Whitehead SA. Phytoestrogens and their low dose combinations inhibit 
mRNA expression and activity of aromatase in human granulosa-luteal cells. The Journal 
of steroid biochemistry and molecular biology 2006; 101:216-225 
23. Whitehead SA, Cross JE, Burden C, Lacey M. Acute and chronic effects of genistein, 
tyrphostin and lavendustin A on steroid synthesis in luteinized human granulosa cells. Hum 
Reprod 2002; 17:589-594 
24. Whitehead SA, Lacey M. Phytoestrogens inhibit aromatase but not 17beta-hydroxysteroid 
dehydrogenase (HSD) type 1 in human granulosa-luteal cells: evidence for FSH induction 
of 17beta-HSD. Hum Reprod 2003; 18:487-494 
25. Myllymaki S, Haavisto T, Vainio M, Toppari J, Paranko J. In vitro effects of 
diethylstilbestrol, genistein, 4-tert-butylphenol, and 4-tert-octylphenol on steroidogenic 
activity of isolated immature rat ovarian follicles. Toxicology and applied pharmacology 
2005; 204:69-80 
26. Whitehead SA, Lacey M. Protein tyrosine kinase activity of lavendustin A and the 
phytoestrogen genistein on progesterone synthesis in cultured rat ovarian cells. Fertility 
and sterility 2000; 73:613-619 
101 
 
27. Basini G, Bussolati S, Santini SE, Grasselli F. The impact of the phyto-oestrogen genistein 
on swine granulosa cell function. J Anim Physiol Anim Nutr (Berl) 2010; 94:e374-382 
28. Tiemann U, Schneider F, Vanselow J, Tomek W. In vitro exposure of porcine granulosa 
cells to the phytoestrogens genistein and daidzein: effects on the biosynthesis of 
reproductive steroid hormones. Reproductive toxicology (Elmsford, NY) 2007; 24:317-
325 
29. Nynca A, Ciereszko RE. Effect of genistein on steroidogenic response of granulosa cell 
populations from porcine preovulatory follicles. Reprod Biol 2006; 6:31-50 
30. Gregoraszczuk E, Slomczynska M, Stoklosowa S. Effect of genistein, tyrphostin and 
herbimycin on prolactin-stimulated progesterone production by porcine theca and luteal 
cells. J Physiol Pharmacol 1999; 50:477-484 
31. Patel S, Peretz J, Pan YX, Helferich WG, Flaws JA. Genistein exposure inhibits growth 
and alters steroidogenesis in adult mouse antral follicles. Toxicology and applied 
pharmacology 2016; 293:53-62 
32. Chan WH. Impact of genistein on maturation of mouse oocytes, fertilization, and fetal 
development. Reproductive toxicology (Elmsford, NY) 2009; 28:52-58 
33. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB, Helferich WG, 
Cooke PS. The soy isoflavone genistein decreases adipose deposition in mice. 
Endocrinology 2003; 144:3315-3320 
34. Benedict JC, Lin TM, Loeffler IK, Peterson RE, Flaws JA. Physiological role of the aryl 
hydrocarbon receptor in mouse ovary development. Toxicological sciences : an official 
journal of the Society of Toxicology 2000; 56:382-388 
35. Borgeest C, Miller KP, Gupta R, Greenfeld C, Hruska KS, Hoyer P, Flaws JA. 
Methoxychlor-induced atresia in the mouse involves Bcl-2 family members, but not 
gonadotropins or estradiol. Biology of reproduction 2004; 70:1828-1835 
36. Hannon PR, Niermann S, Flaws JA. Acute exposure to di(2-ethylhexyl) phthalate in 
adulthood causes adverse reproductive outcomes later in life and accelerates reproductive 
aging in female mice. Toxicological sciences : an official journal of the Society of 
Toxicology 2015;  
37. Flaws JA, Doerr JK, Sipes IG, Hoyer PB. Destruction of preantral follicles in adult rats by 
4-vinyl-1-cyclohexene diepoxide. Reproductive toxicology (Elmsford, NY) 1994; 8:509-
514 
38. Reinli K, Block G. Phytoestrogen content of foods--a compendium of literature values. 
Nutrition and cancer 1996; 26:123-148 
39. Haynes-Johnson D, Lai MT, Campen C, Palmer S. Diverse effects of tyrosine kinase 
inhibitors on follicle-stimulating hormone-stimulated estradiol and progesterone 
production from rat granulosa cells in serum-containing medium and serum-free medium 
containing epidermal growth factor. Biology of reproduction 1999; 61:147-153 
102 
 
40. Couse JF, Yates MM, Sanford R, Nyska A, Nilson JH, Korach KS. Formation of cystic 
ovarian follicles associated with elevated luteinizing hormone requires estrogen receptor-
beta. Endocrinology 2004; 145:4693-4702 
41. Parkening TA, Collins TJ, Smith ER. Plasma and pituitary concentrations of LH, FSH and 
prolactin in aged female C57BL/6 mice. Journal of reproduction and fertility 1980; 58:377-
386 
103 
 
Chapter VI 
Summaries, Conclusions, and Future Directions 
6.1 Summaries, Conclusions, and Future Directions 
The objective of my doctoral dissertation was to determine if and how genistein exposure 
affected ovarian follicle growth, ovarian function, and female reproductive outcomes. Genistein is 
an isoflavone phytoestrogen commonly found in plants and plant products. Humans are primarily 
exposed to genistein through the consumption of soy and soy-based dietary products. Genistein, 
like other botanical compounds, is a nutraceutical compound used as a chemo-preventive agent in 
women undergoing chemotherapy and as a treatment for menopausal symptoms (1,2). However, 
its broader physiological impacts remain unknown. This is of particular concern because genistein 
is a known endocrine disrupting chemical that can bind and signal through estrogen receptors (3). 
It is important to understand how genistein affects ovarian development and hormone production 
in the adult because proper follicle growth and hormone levels are key factors for normal fertility 
and overall female health (4-13). Collectively, my studies show that exposure to environmentally 
relevant doses of genistein inhibits antral follicle growth in vitro, decreases estradiol production 
in vitro, alters gestation time, prolongs parturition time, increases pup mortality, decreases litter 
size, increases pup weight, increases poor maternal behavior, and increases the number of cystic 
ovaries.  
In Chapter 3, I initially hypothesized that genistein exposure would inhibit antral follicle 
growth as a result of decreasing estradiol levels in vivo. However, I found that exposure to genistein 
(36 µM) significantly inhibited antral follicle growth as early as 24 h in culture, whereas estradiol 
levels were not decreased until 72 h of culture. This indicated that estradiol levels did not regulate 
antral follicle inhibition. Since I observed genistein-induced follicle growth inhibition as early as 
24 h in culture, I examined the expression of apoptotic factors and cell cycle regulators at 18 h. I 
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found that genistein did not affect the ratio of Bax and Bcl2 at 18 h, however, genistein (36 µM) 
significantly increased the expression of the cell cycle inhibitor Cdkn1a compared to control. This 
indicates that the initial genistein-induced inhibition of antral follicle growth is likely a result of 
cell cycle arrest and not apoptosis.  
Next, I examined the levels of estradiol precursor hormones and the expression of 
steroidogenic enzymes at each time point. I found that genistein increased progesterone and DHEA 
levels after 48 h in culture compared to control, whereas genistein decreased estradiol and estrone 
levels after 72 h in culture. Examining steroidogenic enzyme gene expression, I found that 
genistein decreased the expression of the enzyme Cyp17a1, the enzyme responsible for further 
metabolizing progesterone and DHEA. Additionally, I found that genistein exposure increases the 
expression of the enzyme Star which is responsible for bringing cholesterol into the theca cell to 
begin the process of estradiol biosynthesis. These results indicate that genistein exposure increases 
progesterone and DHEA levels by decreasing the expression of Cyp17a1; thus, inhibiting the 
metabolism of progesterone and DHEA. Future studies should examine if similar effects can be 
observed at different doses of genistein. 
In Chapter 4, I hypothesized that chronic, preconception exposure to dietary levels of 
genistein adversely affects some fertility and pregnancy outcomes in females. I found that after 30 
days of dosing, genistein exposure (500 and 1000 ppm) decreased gestation time compared to 
control. After 60 days of dosing, genistein exposure increased gestation time (500 and 1000 ppm), 
increased pup mortality (500 and 1000 ppm), decreased litter size (500 ppm), and increased the 
average pup weight (500 ppm) compared to control. After 150 days of dosing, genistein exposure 
(300 ppm) increased the number of dams with prolonged parturition and pup mortality. To 
determine potential cause of pup death, I examined maternal behavior and found that the genistein 
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treated (300 ppm) dams who experienced prolonged parturition were the same dams that lost their 
entire litters. These dams spent 2-3 days in parturition and were therefore unable to properly clean 
and care for their pups, thus neglecting their pups.  
After 240 days of dosing, I observed a natural decline in fertility in our control animals 
(67%). Exposure to 300 ppm genistein decreased fertility rates (50%) compared to control, 
whereas exposure to 1000 ppm genistein maintained 100% fertility.  Additionally, 240 days of 
genistein exposure (500 ppm) increased pup mortality. Again, I examined maternal behavior and 
found that exposure to 500 ppm genistein increased neglectful maternal behavior compared to 
control; thus, resulting in increased pup mortality. These results show that preconception exposure 
to dietary levels of genistein affects gestation time, affects fertility rates, increases pup mortality, 
and increases poor maternal behavior. Future studies should further examine if exposure to 1000 
ppm maintains its protective effect on fertility later in life.  
In Chapter 5, I hypothesized that chronic exposure to dietary levels of genistein affects 
steroid hormone production and ovarian morphology. I also examined wet weights from tissues 
collected at each time point and found that genistein exposure did not change tissue weights after 
30, 60, and 150. However, genistein (500 ppm) increased the average liver weight compared to 
control after 240 days of exposure.  I also found that exposure to low doses of genistein does not 
have significant effects on serum estradiol or progesterone levels at any time point. I did observe 
large variability in my results, therefore, it is possible that if genistein is having any effects on 
hormone levels they are subtle effects and statistical significance cannot be determined with our 
sample size. Future studies should examine should examine the effects of genistein on hormone 
levels using a larger sample size. It would also be beneficial to examine the effects of genistein on 
other sex steroid hormones, such as DHEA and estrone.  
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I also examined follicle numbers after 30 and 60 days of exposure to low doses of genistein 
and found that genistein exposure (300 ppm) significantly increased primary follicle numbers 
compared to control. Additionally, genistein exposure (500 ppm) increased the number of 
primordial follicles compared to control; however, this was of borderline significance. After 60 
days of genistein exposure, I did not observe any statistically significant changes in follicle 
numbers. However, when examining follicle counts from both 30 and 60 days, I observed that 
exposure to 500 ppm genistein increases total follicle numbers, but this change is not statistically 
significant. 
Next, I examined the ovaries of mice dosed with genistein for 240 days then aged to 10 
months. I found that exposure to genistein increased the number of cystic ovaries in a dose 
dependent manner. The control mice had no cystic ovaries, however in the genistein treater groups 
50% (300 ppm), 33% (500 ppm), and 17% (1000 ppm) of mice had cystic ovaries, respectively. 
Collectively these results indicate that chronic exposure to environmentally relevant doses of 
genistein has subtle effects on ovarian follicle numbers after 30 and 60 days of exposure, and 
increases the presence of cystic ovaries in aged mice. Future studies should examine ovarian 
follicle numbers after 150 and 240 days of exposure to genistein. Additionally, future studies 
should examine potential causes of the observed increase in cystic ovaries, potentially by 
measuring LH levels in the serum of aged mice to determine if genistein is causing early 
reproductive senescence.  
Collectively, the results from my doctoral dissertation work indicate that genistein 
exposure inhibits antral follicle growth in vitro by increasing the expression of cell cycle inhibitor 
and causing cell cycle arrest. Additionally, in vitro genistein exposure increases progesterone and 
DHEA levels, and decreases estradiol and estrone levels by altering the expression of steroidogenic 
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enzymes. The results from my in vivo work show that preconception exposure to environmentally 
relevant levels of genistein affects gestation time, increases parturition time, decreases litter size, 
increases pup weight, increases pup mortality, and increases poor maternal behavior. Additionally, 
chronic exposure to environmentally relevant doses of genistein increases primordial and primary 
follicle numbers, and increases the presence of ovarian cysts. Altogether, the findings from my 
dissertation work show that genistein exposure affects female reproductive outcomes.         
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APPENDIX A 
 
CLARITY-BPA is a project I contributed to during the time of Ph.D., but was not a part of my 
dissertation work. The following paper is the result of work done on this project. 
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Bisphenol A Exposure, Ovarian Follicle Numbers, and Female Sex Steroid Hormone 
Levels: Results from a CLARITY-BPA Study 
Shreya Patela, Emily Brehma, Liying Gaoa, Saniya Rattana, Ayelet Ziv-Galb, and Jodi A. Flawsa  
Abstract 
Bisphenol A (BPA) is an industrial chemical found in thermal receipts, and food and 
beverage containers.  Previous studies have shown that BPA can affect the numbers and health of 
ovarian follicles and the production of sex steroid hormones, but they often did not include a wide-
range of doses of BPA, used a small sample size, focused on relatively short-term exposures to 
BPA, and/or did not examine the consequences of chronic BPA exposure on the ovaries or steroid 
levels.  Thus, this study was designed to examine the effects of a wide range of doses of BPA on 
ovarian morphology and sex steroid hormone production. Specifically, this study tested the 
hypothesis that prenatal and continuous BPA exposure reduces ovarian follicle numbers and sex 
steroid hormone levels.  To test this hypothesis, rats were dosed with vehicle, ethinyl estradiol 
(0.05 and 0.5 μg/kg bw/day), or BPA (2.5, 25, 250, 2,500, and 25,000 μg/kg bw/day) from 
gestation day 6 until 1 year as part of the Consortium Linking Academic and Regulatory Insights 
on BPA Toxicity (CLARITY-BPA).  Ovaries and sera were collected on postnatal days 1, 21, 90, 
6 months, and 1 year.  The ovaries were subjected to histological evaluation of follicle numbers 
and the sera subjected to measurements of estradiol and progesterone.   Collectively, these data 
indicate that BPA exposure at some doses and time-points affects ovarian follicle numbers and sex 
steroid levels, but these effects are different than those observed with ethinyl estradiol exposure 
and some previous studies on BPA.   
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Introduction 
Bisphenol A (BPA) is a high volume industrial chemical used in the production of 
polycarbonate plastics and epoxy resins, and in the manufacturing of food and drink containers, 
thermal receipt paper, and dental sealants (1-3). BPA can leach out of these products when exposed 
to high temperatures, ultraviolet rays, acidic or basic compounds, or simply from repeated use. 
Due to its ubiquitous presence in the environment and its ability to leach out of products, humans 
are exposed to BPA daily.  BPA has been measured in numerous human tissues and fluids 
including, but not limited to, urine (4,5), serum (6-8), plasma (9,10), amniotic fluid (11,12), 
placental tissue (13), and fetal serum (13,14). Recently, the World Health Organization and the 
Food and Agriculture Organization of the United Nations estimated the human exposure levels to 
BPA to be between 0.4 and 1.4 µg/kg body weight (bw)/day (15). According to the U.S. 
Environmental Protection Agency (EPA), the currently accepted lowest observed adverse effect 
level (LOAEL) for BPA is 50 mg/kg bw/day, and the EPA safe reference dose  is 50 µg/kg bw/day 
(16). However, BPA can potentially have adverse effects at lower doses and induce effects with a 
non-monotonic dose-response (17-19). 
Several experimental studies have examined the effects of BPA on the ovary (20).  These 
studies focused on the effects of BPA on follicle numbers and sex steroid hormone production 
because the normal production of ovarian follicles and sex steroid hormones is required for female 
fertility (21).  Some of these animal studies indicate that exposure to BPA alters ovarian follicle 
numbers, but the types of alterations differ between studies and largely depend on the dose of BPA, 
the ovarian outcome examined, and/or the window of exposure. Rivera et al. (2011) reported that 
neonatal exposure to BPA (50 µg/kg bw/day) by subcutaneous injection decreases the primordial 
follicle pool and increases the number of multi-oocyte and atretic follicles in lambs at postnatal 
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day (PND) 30 (22).  Rodriguez et al. (2010) reported that neonatal exposure to BPA (20 mg/kg 
bw/day) by subcutaneous injection reduces the primordial follicle pool in rats at PND 8 (23).  
Further, in utero exposure to oral BPA (0.5, 20, and 50 µg/kg bw/day) disrupts germ cell nest 
breakdown in female offspring in mice at PND 4 (24).  
Some animal studies also indicate that BPA exposure disrupts steroidogenesis, but the 
types and degrees of alteration differ between studies, likely due to differences in dose of BPA, 
route of exposure, and/or timing/length of exposure (20). Specifically, studies indicate that 
exposure to BPA increases serum estradiol levels in mice and rats (25,26); however, other studies 
indicate that exposure to BPA does not affect steroidogenesis except at 100 and 300 mg BPA/kg 
bw/day in rats (27-29).  
Although these previous studies provide important information on the effects of BPA on 
the ovary and steroid production, they often did not include a wide-range of doses of BPA or did 
not control for potential unintended exposure to other compounds with estrogenic activity, such as 
dietary phytoestrogens.  Furthermore, previous studies only focused on relatively short-term 
exposures to BPA and did not examine the consequences of chronic BPA exposure on the ovaries 
or steroid levels.  Thus, the purpose of this study was to test the hypothesis that prenatal and 
continuous BPA exposure affects folliculogenesis and the production of sex steroid hormones in 
female rats.  This hypothesis was tested as part of the Consortium Linking Academic and 
Regulatory Insights on BPA Toxicity (CLARITY-BPA) program. The CLARITY-BPA study is a 
collaboration between academic and federal government scientists, organized by the National 
Toxicology Program (NTP), the National Institute of Environmental Health Sciences (NIEHS) and 
the U.S. Food and Drug Administration (FDA) National Center for Toxicological Research 
(NCTR) (30,31). The goal of this research consortium is to combine the strengths of both academic 
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and guideline-compliant studies to obtain better translational research (30,31). The CLARITY-
BPA studies included a wide range of BPA doses ranging from 2.5 µg/kg bw/day to 25,000 µg/kg 
bw/day, as well as two doses (0.05 and 0.5 µg/kg bw/day) of a reference estrogen control (ethinyl 
estradiol; EE2). Exposure by oral gavage began on gestation day 6 and continued by direct dosing 
of the pups after birth until weaning at postnatal day (PND) 21 (stop dose arm) or continuously for 
up to 1 year.  
 
Methods 
This study was conducted as part of the CLARITY-BPA Consortium. The methods for this 
consortium have been published in detail (31), but are briefly described below.   
Reagents 
 BPA (CAS # 80-05-7, TCI America Portland OR, catalog # B0494, Lot # 111909/AOHOK 
(air-milled), >99% pure) and EE2 (CAS # 57-63-6, Sigma-Aldrich Chemical Co. St Louis MO, 
catalog #E4876,  Lot # 071M1492V, >99% pure) were used in these studies (29). The purities of 
BPA and EE2 were verified at 6-month intervals during the study and again at the end of the study 
to confirm test particle stability.  The vehicle used to deliver BPA and EE2 was 0.3% aqueous 
carboxymethylcellulose (Sigma-Aldrich; St. Louis, MO; catalog # C5013, Lot # 041M0105V).   
 
Animals 
NCTR Sprague-Dawley rats (Strain Code 23) from the NCTR rodent breeding colony were 
used in all experiments.  Breeders were housed in polysulfone cages with hard chip bedding and 
glass water bottles in rooms at 23 ± 3ºC with a relative humidity of 50 ± 20%, and provided food 
(soy- and alfalfa-free verified casein diet 10 IF, 5K96, Purina Mills, Richmond, IN; catalogue # 
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1810069) and water for ad libitum consumption from weaning (approximately PND 21), and their 
offspring were housed under the same study conditions from birth.  All animal rooms were under 
12-hour light/dark cycles, with lights on at 6 AM.  All animal use and procedures were approved 
by the NCTR Laboratory Animal Care and Use Committee and conducted in an Association for 
Assessment and Accreditation of Laboratory Animal Care (AALAC)-accredited facility.   
 
Dosing 
Timed-pregnant rats were dosed by gavage with vehicle control (0.3% 
carboxymethylcellulose), five different doses of BPA (2.5, 25, 250, 2,500, and 25,000 μg/kg 
bw/day), and two doses of EE2 (0.05 and 0.5 μg/kg bw/day) from gestation day 6-until the start of 
labor.  Starting on PND1 (day of birth is PND 0), the pups were directly gavaged with the same 
dose level of vehicle, BPA, or EE2 as their dams.  Each dose group was split into two dosing arms, 
a continuously dosed group and a stop dose group, with the latter having treatment terminated at 
weaning on PND 21.   
The selected doses of BPA were based on the results from a 90-day BPA study conducted 
by NCTR prior to the CLARITY-BPA Program (29), estimates of human exposure levels (1,20), 
and agreement among NIEHS-funded university-based researchers and NTP and FDA scientists 
to focus on a dose range of regulatory concern.  Furthermore, the NIEHS-funded university-based 
researchers in the CLARITY-BPA program agreed to include two doses EE2 (0.05 and 0.5 µg/kg 
bw/day) to determine the sensitivity of the animal model to EE2.   
All doses were administered at NCTR by daily gavage with a modified Hamilton 
Microlab® ML511C programmable 115V pump (Hamilton Co., Reno, NV; Lewis et al., 2010).  
Dosing was always conducted from the lowest to highest dose within a dosing pump, and cleaning 
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and maintenance of the equipment were performed as described in Delclos et al. (29).  The 
accuracy of dose delivery from the pumps was assessed every three months and established to be 
within 10% of the target volume accuracy.  
   
 Tissue Collection 
 Pregnant dams were allowed to give birth naturally.  Their pups then were euthanized on 
PNDs 1, 21, and 90, as well as at 6 months and 1 year of age. The current study used samples from 
female offspring (n= 8-10 per treatment group per time point); only 1 female per litter was used 
per treatment group, so no adjustment for litter was needed in the statistical analysis. Cycling 
females were euthanized when predicted to be in estrus based on a vaginal smear from the previous 
day. This method was not always successful in predicting estrous cyclicity on the day of 
collections. Because it is important to measure hormone levels from animals on the same day of 
the estrous cycle, the n is less than 10 in some treatment groups used for hormone analysis. The 
ovaries were collected, and one ovary per animal was fixed in Dietrich’s solution and the other 
was snap-frozen in liquid nitrogen.  The fixed and frozen ovaries were shipped from NCTR to the 
University of Illinois.  The fixed ovaries were used to assess ovarian follicle numbers, as described 
below, and the frozen ovaries were stored at -800 C for future studies.  Furthermore, sera were 
collected from all female offspring, frozen, and shipped from NCTR to the University of Illinois 
for analysis of estradiol and progesterone levels, as described below.  Samples were received from 
both the stop-dose and continuous dosing arms of the study.  All samples were received without 
knowledge of treatment group, and data were not decoded until data collection of follicle numbers 
and hormone levels was complete and the raw data were locked in the NTP Chemical Effects in 
Biological Systems (CEBS) database.  
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Assessment of Ovarian Follicle Numbers 
The fixed ovaries were transferred to 70% ethanol, embedded in paraffin wax, and serial 
sectioned (8 µm) using a microtome. The serial sections were mounted on a glass slide and stained 
with hematoxylin and eosin. Follicle numbers were counted in every tenth section using previously 
defined criteria (32-35). Briefly, primordial follicles contained an oocyte surrounded by a single 
layer of squamous granulosa cells, primary follicles contained an oocyte surrounded by a single 
layer of cuboidal granulosa cells, pre-antral follicles contained an oocyte surrounded by at least 
two layers of cuboidal granulosa cells and theca cells, and antral follicles contained an oocyte 
surrounded by multiple layers of cuboidal granulosa cells with a fluid filled antral space and theca 
cells. All primordial and primary follicles were counted in each section regardless of nuclear 
material in the oocyte, whereas only pre-antral and antral follicles with nuclear material in the 
oocyte were counted to avoid double counting the larger follicle types that can span multiple 
sections. Follicles transitioning between stages were counted as follicles within the more immature 
stage of the two stages. Follicles were considered unhealthy if they showed numerous apoptotic 
granulosa cells or oocyte abnormalities. All other follicles were considered healthy.    
 
Measurement of Estradiol and Progesterone 
The serum estradiol and progesterone levels were quantified by enzyme-linked 
immunosorbent assays (ELISAs) at the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core (estradiol: Calbiotech, Spring Valley CA; 
progesterone: IBL, Minneapolis, MN). The Core used assays that were validated according to the 
Endocrine Society’s Sex Steroid Assay Reporting Task Force (https://med.virginia.edu/research-
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in-reproduction/wp-content/uploads/sites/311/2015/12/Steroid-Method-Valid-Proc.pdf).  The 
assays were read on an EL800 Universal Microplate Reader (Bio-Tek Instruments, Inc.). The Core 
laboratory performed all analyses without knowledge of treatment group. The intra-assay and 
inter-assay coefficient of variations for estradiol were 6.1% and 8.9%, respectively. The intra-
assay and inter-assay coefficient of variations for progesterone were 3.6% and 9.0, respectively. 
 
Statistical Analysis 
Data analysis was conducted using SPSS statistical software (SPSS, Inc., Chicago, IL). In the case 
of data collected from cycling females (PND 90, 6 months, and 1 year), only the data collected 
from females in estrus were used in hormone analysis. Therefore, the n is less than 10 for some 
endpoints. Data were expressed as means and standard error of the means (SEM). Multiple 
comparisons between normally distributed experimental groups were made using one-way 
analysis of variance (ANOVA). In cases when the ANOVA was significant at p ≤ 0.05, Dunnett’s 
2-sided t tests were used to determine which treatment groups were significantly different from 
the control. Non-normally distributed data were analyzed using a Kruskall-Wallis test. BPA and 
EE2 were compared to the vehicle in separate analyses. Statistical significance was assigned at p 
≤ 0.05.  
 
Results 
Effects of EE2 and BPA on Ovarian Morphology on PND 1 
On PND 1, EE2 or BPA exposure did not significantly affect the number of healthy or 
apoptotic germ cells compared to control (Figure 1, n=9-10). It also did not affect the number of 
primordial follicles present in the ovaries compared to control (Figure 1, n=9-10). 
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Effects of Prenatal and Pre-Weaning Exposure to EE2 and BPA on Ovarian Morphology and 
Hormone levels on PND 21 
On PND 21, EE2 exposure did not affect the numbers of any primordial, primary, and pre-
antral follicles, but it decreased antral follicles when compared to control (Figure 2A, n=8-10, 
p<0.05). Exposure to BPA significantly decreased primordial (250 µg/kg bw/day), primary (2.5 
and 250 µg/kg bw/day) and pre-antral (2.5 µg/kg bw/day) follicle numbers compared to control 
(Figure 2A, n=8-10, p≤0.05). Additionally, exposure to BPA (2.5 and 250 µg/kg bw/day) 
significantly decreased the number of total healthy follicles compared to control (Figure 2A, n=8-
10, p≤0.05). 
 
On PND 21, exposure to EE2 or BPA did not affect serum estradiol levels when compared 
to control (Figure 2B, n=8-10). In contrast, exposure to EE2 (0.5 µg 
/kg bw/day) significantly increased serum progesterone levels by approximately 2 ng/ml 
when compared to control (Figure 2C, n=8-10, p≤0.05). Exposure to BPA did not affect serum 
progesterone levels when compared to control (Figure 2C, n=8-10). 
 
Effects of Prenatal and Pre-Weaning Exposure to EE2 and BPA on Ovarian Morphology and 
Hormone Levels on PND 90  
On PND 90, exposure to EE2 or BPA did not affect the numbers of different follicle types 
when compared to control (Figure 3A, n=8-10). Additionally, exposure to EE2 or BPA did not 
significantly affect serum estradiol or progesterone levels compared to control (Figures 2B and 
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2C, n=4-9). EE2 exposure (0.5 µg/kg bw/day) increased serum progesterone levels, but this change 
was not statistically significant when compared to control (Figure 2C, n=7, p=0.058). 
 
Effects of Continuous Exposure to EE2 and BPA on Ovarian Morphology and Hormone Levels 
on PND 90 
On PND 90, continuous exposure to EE2 (0.5 µg/kg bw/day) significantly decreased the 
number of preantral follicles when compared to control (Figure 4A, n=8-10, p≤0.05). However, 
BPA did not significantly affect the number of ovarian follicles when compared to control (Figure 
4A, n=8-10). Additionally, continuous EE2 or BPA exposure did not affect serum estradiol or 
progesterone levels when compared to control (Figures 4B and 4C, n=6-9). 
 
 
Effects of Prenatal and Pre-Weaning Exposure to EE2 and BPA on Ovarian Morphology and 
Hormone Levels at 6 Months 
At 6 months, prenatal and pre-weaning exposure to EE2 (0.5 µg/kg bw/day) significantly 
decreased the number of preantral and antral follicles when compared to control (Figure 5A, n=9-
10, p≤0.05). Exposure to BPA did not significantly affect the numbers of any ovarian follicle type 
when compared to control (Figure 5A, n=9-10). Similarly, exposure to EE2 or BPA did not affect 
serum estradiol or progesterone levels at 6 months when compared to control (Figures 5B and 5C, 
n=5-9).  
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Effects of Continuous Exposure to EE2 and BPA on Ovarian Morphology and Hormone Levels 
at 6 Months 
Continuous exposure to EE2 and BPA did not significantly affect the number of any ovarian 
follicle type at 6 months when compared to control (Figure 6A, n=10). Further, EE2 or BPA 
exposure did not significantly affect most serum estradiol or progesterone levels when compared 
to control (Figures 6B and 6C, n=3-8). However, EE2 exposure (0.5 µg/kg bw/day) decreased 
serum progesterone levels at 6 months (Figure 6C, n=7, p<0.05).  
 
Effects of Prenatal and Pre-Weaning Exposure to EE2 and BPA on Ovarian Morphology and 
Hormone Levels at 1 year 
At 1 year, prenatal and pre-weaning exposure to EE2 or BPA did not significantly affect 
the numbers of most ovarian follicle types, But EE2 (0.5 0.5 µg/kg bw/day) increased primary 
follicles when compared to control (Figure 7A, n=9-10, p<0.05). Additionally, exposure to EE2 or 
BPA did not significantly affect serum estradiol or progesterone levels when compared to control 
(Figures 7B and 7C, n=5-10). 
 
Effect of Continuous Exposure to EE2 and BPA on Ovarian Morphology and Hormone Levels 
at 1 year 
At 1 year, continuous exposure to EE2 (0.5 µg/kg bw/day) significantly increased the 
number of primary follicles present when compared to control (Figure 8A, n=8-10, p≤0.05). 
Exposure to BPA did not significantly affect the numbers of any ovarian follicle types compared 
to control (Figure 8A, n=8-10). Exposure to EE2 (0.05 and 0.5 µg/kg bw/day) significantly 
decreased serum estradiol levels when compared to control (Figure 8B, n=3-9, p≤0.05). 
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Additionally, BPA exposure at 2,500 and 25,000 µg/kg bw/day significantly decreased serum 
estradiol levels when compared to control (Figure 8B, n=3-9, p≤0.05). BPA exposure at 2.5, 25, 
and 250 µg/kg bw/day also decreased estradiol levels compared to control, but this change was not 
statistically significant (Figure 8B, n=3-9). Conversely, EE2 or BPA exposure did not significantly 
affect serum progesterone levels when compared to control (Figure 8C, n=3-9). 
 
Discussion 
 The CLARITY-BPA consortium allowed us to examine the effects of short and long term 
exposure to EE2 and BPA on ovarian morphology and sex steroid hormone production. Our results 
show that exposure to BPA (2.5 and 250 µg/kg bw/day) decreased the numbers of primordial, 
primary, preantral, and total healthy follicle numbers at PND 21. Exposure to EE2 (0.5 µg/kg 
bw/day) decreased preantral follicles (PND 90, 6 months), decreased antral follicles (PND 21 and 
6 months), and increased the number of primary follicles (1 year) when compared to control. 
Additionally, both BPA (2,500 and 25,000 µg/kg bw/day) and EE2 (0.05 and 0.5 µg/kg bw/day) 
exposure decreased estradiol levels in animals dosed for 1 year. Collectively, these results indicate 
that EE2 and BPA exposures at some doses and time-points affect ovarian follicle numbers and sex 
steroid levels in the rat.  The most consistent effects were observed with 0.5 EE2 (Figure 9).  This 
particular treatment significantly affected follicle numbers at PND 21, PND 90, 6 months, and 1 
year.  Further, it altered hormone levels at PND 21, PND 90, 6 months, and 1 year.  Consistent 
effects were also observed with all treatment groups on estradiol levels after 1 year of continuous 
dosing (Figure 9).  Both EE2 treatments and two BPA treatments (2,500 and 25,000 µg/kg bw/day) 
significantly reduced estradiol levels and several BPA treatments (2.5, 25, and 250 µg/kg bw/day) 
caused a borderline significant reduction in estradiol levels (p values ranged from 0.08-0.14).  
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The observed effects of EE2 on follicle numbers are somewhat similar to previous studies 
on EE2.   Specifically, our study as well as studies by Talsness et al. and Delclos et al. indicate that 
prenatal exposure to EE2 reduces the number of preantral and/or antral follicles in the rat ovary 
(29,36).  However, both Talsness et al. and Delclos et al. report that EE2 causes cyst formation in 
the ovary, whereas we did not observe that EE2 causes cyst formation (29,36).  It is likely that the 
differences in our results compared to Talsness et al. stem from differences in the doses of EE2. 
We used 0.05 and 0.5 µg/kg/bw, whereas Talsness et al. used 2 µg/kg/bw of EE2 (36).  It is also 
likely that the differences in our results compared to Talsness et al. stem from differences in the 
source of rats.  We used NCTR Sprague-Dawley rats (Strain Code 23) from the NCTR rodent 
breeding colony, whereas Talsness et al. used Sprague-Dawley rats from Winkelmann, Borchen, 
Germany (36).  However, we cannot explain differences between the results of our study and 
Delclos et al.  Both studies used the same dose of EE2, the same dosing window, the same route 
of exposure, and the same strain of rats. 
The observed effects of BPA on follicle numbers in rats are similar to previous studies on 
the effects of BPA in other species such as lambs and mice.   In our study, BPA exposure at 2.5 
and 250 µg/kg bw/day decreased follicle numbers on PND21.  In a study conducted on lambs, 
Rivera et al. showed that subcutaneous exposure to 50 µg/kg bw/day BPA from PND 1 to 14 
decreased the primordial follicle pool and increased the number of atretic follicles and multi-
oocyte follicles in PND 30 ovaries (22). In a study conducted on mice, prenatal exposure to 0.5 or 
50 µg/kg bw/day BPA decreased the number of primordial follicles present in PND 4 ovaries (24).  
These studies indicate that several species are susceptible to BPA-induced reductions in follicle 
numbers.  Contrary to the mouse and lamb studies, we did not examine follicle populations at PND 
4 or 30   Thus, we may have missed effects of BPA on the PND 4 and PND 30 ovary.   It is also 
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possible that the effects of BPA exposure on the rat ovary may occur at later time-points than in 
the mouse or at earlier time-points than in the lamb.  
Similar to our study, other studies conducted on rats showed that exposure to BPA affects 
follicle numbers. One particular study found that exposure to BPA (0.5 and 50 µg/kg bw/day) from 
gestational day (GD) 9 to PND 21 decreased the number of primary follicles in female Wistar rats 
(37). Another study found that exposure to BPA (3 µg/kg bw/day) from GD 0 to PND 21 increased 
the number of primary, secondary, antral, and total follicle numbers in the ovary when compared 
to control in Wistar rats (38).  Although the effects of BPA on specific follicle populations differ 
between our study and other rat studies, they collectively indicate that prenatal and prepubertal 
exposure to BPA can affect follicle numbers in the ovary.  Any differences in the effects of BPA 
on specific follicle populations likely stem from the different doses and timing of exposure used 
in the various rat studies.     
Previous studies conducted on rats have also examined the effects of BPA on sex steroid 
hormone production. Both Fernández et al. and Gamez et al. showed that BPA exposure (2.5-6.2 
and 25-62 mg/kg, and 3µg/kg bw/day) increased estradiol levels compared to control (26,38).  In 
contrast, our results indicate that continuous exposure to BPA decreased estradiol levels compared 
to control, but only at 1 year. Although both Fernández et al. and Gamez et al used doses similar 
to those in our study, it is possible that differences in the observed effects of BPA on hormone 
levels are the result of different routes of exposure. Fernández et al. administered BPA by 
subcutaneous injection (26). Subcutaneous injection of BPA could result in higher systemic BPA 
levels than oral gavage (39).  Thus, the rats from the study by Fernández et al. could have been 
exposed to higher levels of BPA than the rats in our study, resulting in different effects of BPA on 
estradiol levels.  Gamez et al. administered BPA in the drinking water (38). Although this is a 
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natural route of exposure to BPA, it is difficult to control the exact amount of BPA that each rat 
receives through the drinking water and likely that internal doses of BPA differed from those in 
our study.   
It is also important to note that in our study, the continuous dosed control group had higher 
estradiol levels (~45 ng/ml, Figure 8B) than the stop-dose control group (~25 ng/ml, Figure 7B). 
Thus, it is possible that the statistical differences in the decreases in estradiol levels in the BPA 
and EE2 treated groups at 1 year are due to an unusual control group. However, it is also possible 
that the higher estradiol levels are simply due to normal biological or seasonal variance between 
the stop-dosed animals and continuous-dosed animals.  All hormone analyses were conducted at 
the same time and without knowledge of treatment group.   It is also important to note that we may 
not have had statistical power to observe significant effects of BPA exposure on hormone levels 
at some doses and time-points.  We initially planned to collect and analyze 10 serum samples from 
each treatment group and time-point.  However, cycling females were euthanized when predicted 
to be in estrus based on a vaginal smear from the previous day. This method was not always 
successful in predicting estrous cyclicity on the day of collections. Because it is important to 
measure hormone levels from animals on the same day of the estrous cycle, the sample size was 
less than 10 in some treatment groups used for hormone analysis.  This could have reduced our 
statistical power to observe differences between treatment groups.  In fact, we noticed that several 
BPA treatments reduced estradiol levels compared to controls at 1 year, but this reduction was not 
always statistically significant at the p <0.05 level.  
Interestingly, the observed effects of BPA and EE2 differ from each other, raising questions 
about whether BPA and EE2 work via different mechanisms of action.  It is well known that EE2 
works through estrogen receptors, but it is possible that BPA exerts its effects via different 
125 
 
receptors or that it stimulates/inhibits different estrogen responsive pathways than EE2 in the 
ovarian follicle.  Studies on the effects of BPA on isolated antral follicles from mice indicate BPA 
inhibits follicle growth and induces atresia independently of the genomic estrogenic pathway (40).  
Further, they also indicate that BPA may inhibit follicle growth partially through the aryl 
hydrocarbon receptor pathway (41).  Thus, it is possible that the effects of BPA observed in this 
study occur through nongenomic estrogen pathways or other receptor pathways such as the aryl 
hydrocarbon pathway. 
When comparing our findings to those of published studies from the CLARITY-BPA 
consortium, we observed that many of the effects observed in our study occur at the same doses 
as those shown to cause effects in other CLARITY-BPA studies. Our results show that continuous 
exposure to BPA at 2.5 and 250 µg/kg bw/day decreases the number of primordial, primary, 
preantral, and total healthy follicle numbers present in the ovary at PND 21. Similarly, Arambula 
et al. observed that BPA at 2.5 and 250 µg/kg bw/day increases the expression of Esr1 and Esr2 
in the hypothalamus at PND 1 (42). In another published CLARITY-BPA study, Johnson et al. 
examined the effects of BPA and EE2 doses on the spatial navigational learning and memory in 
rats. They found that female rats exposed to BPA at 2,500 µg/kg bw/day were less likely to locate 
the correct escape box than controls at PND 90 (43). After exposure to the same dose (BPA 2,500 
µg/kg bw/day), we observed decreased serum estradiol levels compared to vehicle control at 1 
year. Although the effects seen in previously published CLARITY-BPA studies occurred at the 
same doses of BPA as our studies, the effects varied by the age of the rats. Therefore, it is difficult 
to state whether the effects observed in different studies are related to each other. However, these 
results indicate that the same doses of BPA have a variety of physiological and behavioral effects 
on the NCTR Sprague Dawley rats. 
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Overall our results indicate that BPA exposure at some doses and time points alters follicle 
numbers and hormone production in female rats. Further, because we observed different effects of 
BPA exposure than EE2 exposure on follicle numbers and hormone levels, it is highly suggested 
that BPA is acting on the rat ovaries in a manner different from EE2. Future studies should examine 
why these two chemicals produce different responses at different doses and time points. 
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Figure A.1 Effects of EE2 and BPA on ovarian morphology on PND 1. 
 
On PND1, pups from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of germ cell and ovarian follicle numbers. The graph represents the means 
± SEM of the number of healthy germ cells, apoptotic germ cells, and primordial follicles present 
in 9-10 ovaries per treatment group. 
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Figure A.2 Effects of EE2 and BPA on ovarian morphology and sex steroid hormones on 
PND 21 
 
On PND21, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 8-10 ovaries per treatment group. (B). This graph represents the means ± SEM 
of the amount of estradiol present in the serum of 8-10 animals per group. (C). This graph 
represents the means ± SEM of the amount of progesterone present in the serum of 8-10 animals 
per group. Asterisks (*) indicate a significant difference between the control group and doses of 
BPA or EE2 (n=8-10; p≤0.05). 
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Figure A.3 Effects of prenatal and pre-weaning exposure to of EE2 and BPA on ovarian 
morphology and sex steroid hormones on PND 90 
    
On PND 90, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 8-10 ovaries per treatment group. (B). This graph represents the means ± SEM 
of the amount of estradiol present in the serum of 4-9 animals per group. (C). This graph represents 
the means ± SEM of the amount of progesterone present in the serum of 4-9 animals per group. 
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Figure A.4 Effects of continuous exposure to of EE2 and BPA on ovarian morphology and 
sex steroid hormones on PND 90 
 
On PND 90, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 8-10 ovaries per treatment group. (B). This graph represents the means ± SEM 
of the amount of estradiol present in the serum of 6-9 animals per group. (C). This graph represents 
the means ± SEM of the amount of progesterone present in the serum of 6-9 animals per group. 
Asterisk (*) indicates a significant difference between the control group and doses of BPA or EE2 
(n=8-10; p≤0.05).  
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Figure A.5 Effects of prenatal and pre-weaning exposure to of EE2 and BPA on ovarian 
morphology and sex steroid hormones at 6 months 
 
At 6 months, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 9-10 ovaries per treatment group. (B). This graph represents the means ± SEM 
of the amount of estradiol present in the serum of 5-9 animals per group. (C). This graph represents 
the means ± SEM of the amount of progesterone present in the serum of 5-9 animals per group. 
Asterisks (*) indicate a significant difference between the control group and doses of BPA or EE2 
(n=9-10; p≤0.05). 
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Figure A.6 Effects of Continuous Exposure to of EE2 and BPA on Ovarian Morphology and 
Sex Steroid Hormones at 6 months 
 
At 6 months, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 10 ovaries per treatment group. (B). This graph represents the means ± SEM of 
the amount of estradiol present in the serum of 3-8 animals per group. (C). This graph represents 
the means ± SEM of the amount of progesterone present in the serum of 3-8 animals per group. 
Asterisk (*) indicates a significant difference between the control group and EE2 (n=9-10; p≤0.05). 
  
134 
 
Figure A.7 Effects of prenatal and pre-weaning exposure to of EE2 and BPA on ovarian 
morphology and sex steroid hormones at 1 year 
 
 
At 1 year, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 9-10 ovaries per treatment group. (B). This graph represents the means ± SEM 
of the amount of estradiol present in the serum of 5-10 animals per group. (C). This graph 
represents the means ± SEM of the amount of progesterone present in the serum of 5-10 animals 
per group.  Asterisk (*) indicates a significant difference between the control group and EE2 (n=9-
10; p≤0.05). 
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Figure A.8 Effects of continuous exposure to of EE2 and BPA on ovarian morphology and 
sex steroid hormones at 1 year 
 
 
At 1 year, rats from each group were euthanized and one ovary from each animal was fixed for 
histological evaluation of different ovarian follicle types. Additionally, serum was collected from 
the blood of each of the animals and used in the measurement of sex steroid hormones. (A). This 
graph represents the means ± SEM of the number of the different follicle types and total healthy 
follicles present in 8-10 ovaries per treatment group. (B). This graph represents the means ± SEM 
of the amount of estradiol present in the serum of 3-9 animals per group. (C). This graph represents 
the means ± SEM of the amount of progesterone present in the serum of 3-9 animals per group. 
Asterisks (*) indicate a significant difference between the control group and doses of BPA or EE2 
(n=3-9; p≤0.05). Arrows (^) indicate p value greater than 0.05. 
  
136 
 
Figure A.9 Heat map depicting the effects of EE2 and BPA exposure on ovarian morphology 
and sex steroid hormones 
 
 
Data from Figures 1-8 were used to generate a heat map. The light pink color shows non-significant 
findings between controls and treatment groups. Darker shades of pink-red correspond to 
significant differences between control and treatment group (with the lowest p-values being the 
darkest colors). 
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